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IDENTIFYING PROTEIN KINASE TBK1 AS A NOVEL INHIBITOR OF
INTESTINAL TUMORIGENESIS

Amber Lynn Mathews, M.S.

Advisory Professor: Shao-Cong Sun, Ph.D.

Colorectal cancer (CRC) is the third most common cancer diagnosed in women and
men， causing almost 600,000 annual deaths worldwide. There is a clear need to
understand how CRC forms and progresses in order to improve the strategies of
CRC prevention and therapy. A major factor that drives the development of CRC is
genetic mutations that lead to activation of oncogenes and inactivation of tumor
suppressor genes in intestinal epithelial cells (IECs). In addition, the initiation and
progression of CRC involve environmental and immunological factors. In particular,
chronic inflammatory conditions are known as an important risk factor for CRC.
Intestinal inflammation can be caused by deregulated signaling events in IECs or
immune cells; and chronic inflammation is often associated with reduced production
of immunosuppressive cytokines such as interleukin (IL)-10 and aberrant production
of inflammatory cytokines. However, the signaling factors involved in the regulation
of intestinal inflammation and tumorigenesis are still poorly defined. Given the
complexity of the molecular and cellular components contributing to these
pathogenic processes, animal models represent an important tool for CRC studies.
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This dissertation focuses on the study of a serine/threonine kinase, TANK
Binding Kinase 1 (TBK1). Although TBK1 is best known as a mediator of type I
interferon induction in antiviral innate immunity, recent evidence suggests the
involvement of TBK1 in several other biological processes including cancer
development. Based on in vitro studies using cancer cell lines, TBK1 has been
implicated as an oncogenic kinase that mediates survival of KRAS-dependent lung
and other cancers. However, the oncogenic role of TBK1 is controversial, since this
finding has been challenged by a more recent study. Moreover, the in vivo role of
TBK1 in CRC development, particularly during the early phase of adenoma
formation, has not been studied. This dissertation project took an in vivo approach
that involves the generation and characterization of an innovative mouse model in
which Tbk1 is conditionally ablated in IECs. The data from my dissertation reveals
an unexpected finding that TBK1 has a tumor-suppressive function in the intestine.
IEC-specific Tbk1 ablation promotes adenoma formation in mice carrying a mutation
in the Apc gene, a tumor-suppressor gene commonly mutated in the early stages of
colon cancer development.

Interestingly, Tbk1 expression is important for the

crosstalk of IECs with intraepithelial lymphocytes that maintain the expression of
immunosuppressive cytokine IL-10. These studies present the first in vivo model
demonstrating the function of TBK1 during the process of intestinal adenoma
development and suggest a mechanism of TBK1 action. These data also present a
novel approach in determining the in vivo function of TBK1 early in the tumorigenic
process as compared to previous findings based on the xenograft model of late-
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staged cancers. In addition, because the use of TBK1 inhibitor has been suggested
for possible treatment in cancers of other tissue types, my findings argue for the
precaution in the selection of treatment modalities targeting TBK1 in these patients;
it is possible that long-term use of TBK1 inhibitors may pose an increased risk for
adenoma growth in the intestine.
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CHAPTER 1: SPECIFIC AIMS OF THE DISSERTATION

1

Chapter 1: Specific Aims of the Dissertation
Colorectal cancer (CRC) is a major cause of cancer morbidity and mortality,
and almost 150,000 people are diagnosed and approximately 50,000 die from this
disease every year in the United States alone. The development of this disease
results from dysregulated signal transduction in intestinal epithelial cells (IECs) that
allows out-of-control growth and/or survival of dysfunctional cells. Several risk
factors have been associated with CRC, including somatic and germline gene
mutations, chronic intestinal inflammation, diet and lifestyle. While there has been
progress in the field, the worldwide incidence of almost 1.2 million people and
mortality rate of almost 600,000 suggest that there is indeed much to understand
concerning the intestinal tumorigenic process in order to improve the strategies of
CRC prevention and treatment. The molecular mechanisms that regulate the
process of CRC initiation and progression are still poorly understood. The overall
objective of my dissertation project has been to contribute to the understanding of
the mechanisms that control intestinal adenoma development. This dissertation
project contributes to this goal by specifically identifying TANK binding kinase 1
(TBK1) as a novel negative regulator of intestinal tumor growth using an innovative
in vivo model.
TBK1 is a serine/threonine protein kinase that mediates type I interferon
induction in antiviral innate immune responses. In addition, recent studies using in
vitro cell culture and xenograft mouse models implicate TBK1 as an oncogenic
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kinase that supports the survival and drug resistance of human cancer cell lines,
including those derived from breast cancer, KRAS-driven lung cancers, melanoma,
and prostate cancer. However, a more recent study showed that the viability of
KRAS-mutant cancer cell lines did not correlate with the knockdown or
pharmacological inhibition of TBK1 in vitro, thus creating controversy in the field. In
addition, our understanding of the function of TBK1 in cancer is limited by the sole
use of cell line studies, which models late stages of disease. Therefore, the role of
TBK1 in regulating the early stage of tumor development, such as the initiation and
growth of adenomas was not yet addressed. Secondly, the use of mouse xenograft
models excludes the contribution of functional T lymphocytes to the understanding of
disease progression. Third, the use of a limited number of human cancer cell lines
may create variations in results due to the accumulation of different genetic
alterations. To overcome these limitations, my dissertation project employed a new
mouse model harboring TBK1 deficiency specifically in IECs. My hypothesis is that
TBK1 modulates intestinal tumorigenesis in vivo by regulating IEC survival and
immune homeostasis.
In testing this hypothesis, my project sought and accomplished the following
specific aims. In Specific Aim 1 (discussed in Chapter 3), we examined the role of
TBK1 in intestinal adenoma development by analyzing the effect of IEC-conditional
Tbk1 knockout on adenoma formation in Apcmin/+ mice and determined that TBK1 in
IECs regulates intestinal tumorigenesis in vivo. These findings were consistent with
a strong correlation between TBK1 and APC mRNA expression in patient samples of
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colorectal adenocarcinomas profiled in The Cancer Genome Atlas (TCGA).

In

Specific Aim 2 (also discussed in Chapter 3), we devised a series of immunological
studies to examine whether TBK1 in IECs regulates intestinal immune homeostasis
in vivo thus affecting the tumorigenic process. In this aim, we determined that TBK1
expression is important for the crosstalk of IECs with intraepithelial lymphocytes
(IELs) that maintains an immunosuppressive environment during intestinal adenoma
development.

In addition to these in vivo studies, we carried out in vitro and

xenograft studies in Specific Aim 3 (discussed in Chapter 4) using TBK1knockdown human CRC cell lines. We determined that TBK1 is dispensable for the
growth of KRAS-competent xenograph tumor growth in immunocompromised hosts.
The findings presented herein supporting the in vivo function of TBK1 in intestinal
tumorigenesis provide a better understanding of the molecular mechanisms
mediating the disease process.

The significance of these findings is discussed

within each chapter of the dissertation with a particular focus in Chapter 5
highlighting further implications.
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CHAPTER 2: LITERATURE REVIEW

5

Chapter 2: Literature Review
Epidemiology
Colorectal cancer is one of the leading cancer diagnoses globally.

The

estimated new diagnoses of CRC is approximately 1.2 million being the second most
common cancer diagnosis in women and third in men1,2. The rate of incidence is
highest in Australia, New Zealand, North America and Europe. In fact, as compared
to developing countries, the rates are as many as five times higher in developed
countries, although differences in methods of medical diagnostics in these regions
may have partially contributed to these epidemiological numbers. However, the
recent trend is a steadily reduced incidence rate in economically developed
countries as a result of screenings and adenomatous polyp removal. At the same
time, a rise in incidence is observed in developing countries, which is attributed to
environmental risk factors such as diet and lifestyle. The time of diagnosis also
varies between developed and developing countries where late stage diagnosis is
more common in developing counties and reflected in mortality rates. There are
about 600,000 estimated worldwide deaths per year from CRC with highest mortality
rate observed in Southern Africa, central and eastern Europe and Eastern Asia as of
2008.1 Because of advancement in screenings, treatments and knowledge of
disease course, there has been a decline in mortality in western countries.1
However, the challenge remains as mortality rate for CRC is substantial.
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It is estimated that nearly 140,000 Americans were diagnosed with CRC while
50,000 succumbed to the disease in 20143. It is currently the third most common
cancer diagnosis and cause of death among both women and men, despite a trend
that has steadily declined since the early 1950s when CRC was the leading cause of
cancer death4,5. The incidence and mortality rates for CRC is greater in men than in
women. Reasons for gender differences are unknown but speculated to be related to
differences in sex hormones, risk factors, and adherence to recommended
screenings6.
Those aged 65 years old and older hold the majority of new cases at 60
percent and CRC deaths at 70 percent6. While an overall decline has been observed
in CRC incidence and mortality rates over the past few decades5, a closer look at
age related trends revealed that the decline in new cases is observed for those 50
years and older whereas a steady increase in CRC incidence amongst younger
adults particularly those 49 years of age or younger6,7. It is predicted that this rate
will continue upward in younger adults below the age of 50 years old, the traditional
CRC screening age. Patients at higher risk, such as those with ulcerative colitis or
family history of inherited CRC, are advised to undergo CRC screening prior to age
50 to allow for earlier diagnosis and treatment. It is believed that the disparity in
age-related CRC incidence is associated with dietary risk factors such as the
pervasiveness of obesity and an inactive lifestyle in the younger population7,
although further research is necessary to determine specifically the effects of these
behavioral risk factors in CRC incidence in younger groups.
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A study performed between 2006 and 2010 revealed a trend demonstrating
differences amongst races and ethnicities, where African Americans have the
highest rates of incidence and mortality while Asian and Pacific Islanders have the
lowest6. There is an association between socioeconomic status and risk of incidence
and mortality from CRC such that low socioeconomic status has higher risk for CRC.
It is believed that the impact of disproportionately low social economic position of
African Americans contributes to this imbalance of new cases and death between
groups as the poverty rate was almost three times and two and half times higher
amongst African Americans as compared to Caucasians and Asians, respectively.6
However, other contributing factors, some of which are still unknown, are
considered, as rates are still considerably higher in African Americans when
compared with Caucasians who are within the same socioeconomic group.

For

example, one recent study suggests that behavioral risk factors may come into play
such as obesity6. While there has been a decline over the more recent years in CRC
rates5,6, it is clear that there is a need to better understand the relationship between
risk factors such as diet and lifestyle in addition to others including somatic and
germline mutations and chronic intestinal inflammation in the development of CRC.
Intestinal epithelia and immune homeostasis – the norm
The intestine is an organ with diverse functions, including food digestion, nutrient
and water absorption, gas exchange, microbial sensing and immunological
regulation. Pivotal to the functions of intestine is the epithelium, the largest mucosal
surface of the body that serves as both a physical barrier to commensal microbes
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and an important component of the immune system. The intestinal epithelium is
covered by a single layer of IECs, including enterocytes, goblet cells, paneth cells,
endocrine cells and M cells, which work together to maintain homeostasis within the
gut. These cells, originating from pluripotent intestinal epithelial stem cells, make up
part of the mucosa, one of the four main vertical layers of the intestine8. Within the
mucosa, IELs, predominately CD8+ T cells, are interspersed throughout and in direct
contact with the epithelial cell layer as illustrated in Figure 1; this puts them along
with the IECs at the forefront of the intestinal immune response. As part of the
mucosa, the lamina propria, which lies beneath a basal membrane or thin layer of
connective tissue under the IEC and IEL layer, is formed by a network of loose
connective tissue that defines a compartment for heavily infused circulating immune
cells, particularly T lymphocytes, macrophages, plasma cells, eosinophils, and mast
cells8. These immune cells are less frequently within the submucosa, the second
layer of the intestine, since a thin smooth muscle layer called the muscularis
mucosa8, a facilitator in movement and mucosal folding, acts as a divider between
the mucosa and the submucosa8,9. Within the submucosa lie larger vessels of the
blood and lymphatic systems, nerve fibers and ganglia supported by loose fibrous
connective tissue. Surrounding the submucosa is the muscularis propria that
consists of two layers of smooth muscle that function in contractility of the gut9. The
outer most layer of the intestine is the serosa, a thin layer of loose connective tissue
that connects to outer muscularis8,9. Throughout the intestine, there are widely
dispersed gut-associated lymphoid tissues (GALT), such as Peyer’s patches in the
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small intestine and colonic patches and isolated lymphoid follicles in the large
intestine, which are organized aggregates of immune cells mediating mucosal
adaptive immune responses9-11.
The epithelial tissues of the intestine undergo specific programs of self-renewal
such that new cells are created every 10 to 14 hours from a dividing intestinal stem
cell population, capable of differentiation while migrating from the crypt to the tip of
the villus. As the cells continue to migrate toward the tip, they undergo apoptosis
such that the layer of epithelium is regenerated every three to five days in a human
and every two to three days in mice. The exceptions are Paneth cells in the small
intestine and enteroendocrine cells, which are renewed less frequently, four weeks
and 35-100 days, respectively8,9. A large portion of pluripotent intestinal stem cells
differentiate into absorptive enterocytes while smaller specialized lineages include
secretory enteroendocrine, goblet and Paneth cells.

Enteroendocrine cells,

neuroendocrine regulators in the intestine, secrete several hormones needed for
proper digestion. Goblet cells are major producers of mucin proteins, especially
mucin 2, which form a mucous layer over the mucosa. Goblet cells also produce
proteins such as Trefoil factor 3, a protein that provides structural support for
mucous layer integrity and signals the promotion of epithelial cell repair mechanism.
Trefoil factor 3 together with muc2 adds additional level of protection against
intestinal pathologic microbial stimuli. Paneth cells at the base of the crypt of the
small intestine release antimicrobial molecules in larger quantities and variety than
that of absorptive enterocytes.

Whereas enterocytes secrete the C-type lectin
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REGIII gamma, which targets destruction of peptidoglycan walls of gram-positive
bacteria, Paneth cells secrete defensins, lysozymes, and cathelicidins which defend
against broader groups of bacteria. By way of active transcytosis, IECs also facilitate
the release of antibodies, particularly IgA produced by lamina propria plasma cells,
into the lumen. This joint effort between plasma cells and IECs maintains
homeostasis by regulating microbial populations in the luminal compartment12.
IECs also have the ability to sample antigen from within the lumen. While it has
traditionally been thought that epithelial microfold cells or M cells uniquely had the
ability to engulf and transcytose microbial antigens into the Peyer’s patches, a recent
study has reported that goblet cells can function similarly, transporting antigen to
lamina propria dendritic cells12,13. Intestinal dendritic cells that are in direct contact
with IECs are also capable of sampling antigens directly within the lumen by using
their dendrites that can cross the epithelial monolayer. It is not yet well understood
how these different ways of antigen sampling functionally impact immune responses,
but it is speculated that the different antigen-sampling cells may direct different types
of immune responses12.
In addition to mediate digestive process via digestive enzyme production, nutrient
absorption, and antimicrobial peptide secretion, the IECs can actively sense
commensal bacteria and pathogens and secrete cytokines and chemokines that are
important for protective immunity and homeostasis of the intestine14. Recognition of
microbe-associated molecular patterns by the IECs relies on the expression of a
variety of pattern recognition receptors (PRRs), including toll-like receptors (TLRs),
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RIG-I like receptors (RLRs) and nucleotide-oligomerization domain (NOD) like
receptors (NLRs). Until recently, the focus of PRR studies has been on their role in
eliciting a proinflammatory response in hematopoietic cells.

However, it is

increasingly clear that the PRRs of IECs play an important role in facilitating immune
tolerance

to

commensal

microbiota

and

maintaining

intestinal

immune

homeostasis12. A major role of the IECs is to prevent invasion by the commensal
bacteria, although it is also likely that IECs may interplay with immune cells to
directly participate in immune tolerance. In this regard, several types of immune cells
contribute to the establishment of immune tolerance to commensals and
maintenance of immunosuppressive environment in the gut; these include IELs,
regulatory T cells, and intestinal macrophages. These immunosuppressive cells are
designed to promote a tolerogenic response and prevent active inflammation in
response to nonthreatening commensals in the lumen or harmless antigen from the
diet11,14 15.
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Colorectal cancer pathology
It is widely recognized that CRC develops in a stepwise fashion driven by
accumulated genetic alterations and environmental factors. Genetic mutations in
intestinal stem cells may result in deregulation of growth- or survival-related
signaling events, thereby altering homeostatic conditions that lead to formation of
aberrant crypt foci, in which crypts appear to be larger than normal16,17. These
putative precancerous lesions are believed to eventually form gastrointestinal
neoplasia (GIN) or microadenomas, microscopic areas of dysplasia. The continuous
growth of these lesions results in the formation of macroscopic polyps termed
macroadenoma or adenoma for short, characterized by grossly visible dysplastic
epithelium

that

have

not

invaded

through

the

muscularis

mucosae16,17.

Advancement of the adenoma growth through the muscular mucosae renders it an
adenocarcinoma, the malignant and thus deadly stage of disease (Figure 1).
Apc mutant animal models for the study of CRC
Although the exact etiology for CRC is still elusive, several genetic mutations,
both somatic and germline, as well as epigenetic changes have been linked to the
development of this malignancy. In particular, patients with familial adenomatous
polyposis syndrome (FAP) inherit a germline mutation in adenomatous polyposis coli
(APC) gene in one allele. The loss of the second allele occurs within 30 years. As
APC functions as a negative regulator of the Wnt signaling pathway, it controls the
level of the active transcription factor β-catenin. The loss-of function mutation in the
APC gene leads to accumulation of β-catenin within the nucleus, causing
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uncontrolled induction of Wnt target genes and aberrant division of intestinal stem
cells and IECs to form pre-cancerous cells and develop into microadenomas and
adenomas16. Somatic mutation in APC is also commonly found in those with
sporadic disease where the inactivation of APC gene occurs over time as a result of
environmental exposures18.
One of the first animal models of CRC was a randomly mutagenized mouse,
carrying a mutation in the Apc gene that leads to expression of truncated form of
APC protein19. The mutant mice spontaneously develop multiple intestinal neoplasia
in the small intestine of the mice, from which the name Apcmin was given. While this
first model involves Apc truncating mutation at codon 850, subsequent knock in
mutations to introduce Apc truncations at codon 716 or 1638 resulted in a similar
phenotype. The variation in truncating sites in the Apc gene was performed to test
whether the shorter truncation in the Apcmin/+ model as compared to those seen in
human patients altered the observed phenotype. Most of the various Apc truncating
mutations resulted in overall similarity with polyp formation predominately in the
small intestine of the mice except in a model where a frameshift at codon 1309,
where polyps were distributed throughout the small intestine and colon, which more
closely resemble the phenotype in patients who have colonic polyps as a result of
APC LOH20. However, the Apcmin/+ model continues to be the primary model used in
studies seeking to identify additional genes involved in intestinal tumorigenesis.
Though the small intestine is the predominant location for adenoma formation in the
Apcmin/+ mice, polyps form in the colon but less frequently21. However, high numbers
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of microadenomas can be found in the colon of Apcmin/+ mice, which resemble those
of the small intestine in that LOH of Apc and β-catenin nuclear accumulation are
evident22.

The Apc716 model demonstrated that the LOH of the Apc allele in

proliferating cells located at the base of the crypt is the initiating step to aberrant
crypt foci or early lesions in the mucosa21. Mice homozygous for the mutant Apcmin
die during embryogenesis22. Additional evidence of APC interaction with
microtubules and Rac-specific guanine nucleotide exchange factor Asef to regulate
actin cytoskeletal rearrangement and cellular morphology supports the idea that
APC is needed for proliferating cells to travel to the tip of the villus. Thus, the loss of
APC in these cells would result in reduced Asef activity and decreased capacity to
move and shed. Furthermore, APC interaction with proteins Asef2 and IQGAP1 also
was reported to effect cell migration and polarity21. Additionally, mice heterozygous
for Apcmin have displayed a gradual reduction in immature and mature T cells in the
thymus and in immature and progenitor B cells in the bone marrow as well as a
depletion of natural killer cells in the spleen.

Further bone marrow transplant

experiments revealed that this phenotype was due to an aberration in the
nonhematopoietic compartment of the bone marrow of Apcmin/+ mice as a result of
decreased mesechymal progenitor cell population where single mesenchymal
precursors derived from Apcmin/+ mice displayed less colony forming units than that
of wildtype mice23.
The inability to maintain mucosal immunological homeostasis could influence
the outcome of polyp formation in this model. In fact, not long after this study,
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another group from MIT found that transferring wildtype CD4+CD25+ lymphocytes
into the Apcmin/+ mice lessened tumor burden24. Based on these two studies, one
could speculate that the depletion of thymocytes as Apcmin/+ mice age may result in
reduced regulatory lymphocyte populations in the periphery tissues, specifically the
small intestine where the maintenance of tolerance is compromised. By transferring
CD4+CD25+ lymphocytes from interleukin (IL)-10 knockout mice, this study further
showed that the IL-10 production by CD4+CD25+ cells was necessary for enhanced
cellular apoptosis and diminished expression of cyclooxygenase- (COX-) 2 and
proinflammatory cytokine genes within polyps of the Apcmin/+ mice24. A paper
published in 2012 reported increased expression of several proinflammatory
cytokines, including TNF-α, IL-6, and IL-1β, in the small intestine of older Apcmin/+
mice as compared to young Apcmin/+ mice, which is positively correlated with
abundance of large polyps25. While the authors of this publication did not compare
the levels of these proinflammatory mediators to wildtype animals, one could
speculate that the loss of APC affects immunosuppressive mechanisms in the small
intestine of the Apcmin/+ mice which may lead to a proinflammatory environment that
favors the formation and growth of polyps.
The Apcmin/+ model has been used to identify several key players in the
promotion and inhibition of intestinal adenoma development. Of particular
importance is the proinflammatory enzyme COX-2, whose ablation reduces polyp
formation in the Apcmin/+ model. Furthermore, Cox-1 mutation in Apcmin/+ mice also
causes reduction in polyp formation, similar to that of Cox-2 deficiency. Further
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studies demonstrate that both COX-1 and COX-2 stimulate angiogenesis in polyps
by generating prostaglandin E2 (PGE2). COX-2 is expressed in both adenomatous
polyps and malignant tumors and is now considered a common feature of tumors of
the intestine. As a result of the findings from basic research, a COX-2 inhibitor,
Celecoxib, has been developed and shown to significantly reduce the number of
polys in FAP patients after six months of treatment26. However, some of the patients
with sporadic disease treated with the COX-2 inhibitor in a later clinical trial suffered
from cardiovascular side effects from the drug. As a result, physicians prescribing
nonsteroidal anti-inflammatory drugs to patients must consider their level of risk for
cardiovascular side effects and proceed with careful medical supervision21. In
addition to Cox-2, the BubR1 and Cdx2 genes were identified as regulators of
genomic stability in the Apcmin/+ and Apc716 models, respectively.

Mutations in

these genes resulted in higher numbers of intestinal polyps and rates of
chromosomal instability in each respective model. The Apc models of CRC also
gave insight into the effect of diet and exercise on the progression of disease.
These models demonstrated that high fat diets accelerate with polyp formation while
calorie-restricted diets significantly reduced polyp numbers. Exercise has also been
shown to reduce polyp burden in the Apcmin/+ model, suggesting the need for dietary
and exercise considerations in overall management of disease21.
Apc mutant mice typically display only the formation of benign intestinal
polyps that rarely advance to malignancy. This model was useful in identifying the
gene Smad4 as a player involved in progression of adenoma to adenocarcinoma.
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Consistent with the involvement of Smad4 in TGF-β signaling, mice with Smad4
deficiency in the Apcmin/+ background display similarities to patients with colon
cancer associated with TGF-β type II receptor mutations21. Phosphatidylinositol 3kinase (PI3K)/Akt pathway has also been associated with colorectal cancer. Apcmin/+
mice with heterozygous mutation in the gene encoding PTEN, a negative regulator of
PI3K pathway, development large invasive adenocarcinomas21. Similarly, invasion of
polyps into the muscularis mucosae was observed in about half of a group of
Apcmin/+ mice with Ephb3 homozygous gene knockout22.
Additional mouse models exist such as β-catenin mutant mouse model in
recapitulating inherited disease syndromes which are less frequently used, likely due
to greater percentage of sporadic colorectal patients, approximately 80 percent, who
possess the Apc gene mutation as compared to 10 percent who carry mutation in βcatenin gene21,27.
Inflammation and colon cancer
There was an early suggestion linking inflammation to cancer in the 19th
century when pathologist Rudolf Virchow predicted that chronic inflammation and
irritation may be a key player in cancer, an idea that was largely ignored as the main
scientific focus was on intrinsic events within the premalignant cells that drive cancer
development28,29. Most recently, many studies have provided evidence in support of
the idea that cancer can evade immune destruction and is also stimulated by some
inflammatory mediators or inflammatory disease conditions16,28. Now both cancer
immune evasion and chronic inflammation have been included as hallmarks of
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cancer30. Epidemiological studies over the last fifteen years have revealed an
estimate of about 20 percent of cancer deaths occur in the context of inflammation
and infection28. The idea of linking tumor formation and inflammation is particularly
important in the intestine, where inflammatory disorders have been associated
colorectal cancer.

Increased risk for CRC has been observed in patients with

chronic inflammatory diseases of the intestine, such as ulcerative colitis or chronic
inflammatory bowel disease31. In fact, about 20 percent of patients with IBD develop
colitis-associated cancer, a subtype of CRC that is fatal in more than 50 percent of
these cases16. It has also been shown that an inflammatory component is involved in
other types of CRC that lack grossly visible inflammation but have immune cell
infiltrates and proinflammatory cytokine production within intestinal polyps16. In fact,
the advancement of adenoma development in Apcmin/+ mice correlates with
increased expression of proinflammatory mediators (Figure 2). As mentioned in a
previous section, the use of the Apcmin/+ model identified that loss of Cox-2, an
enzyme involved in promoting inflammation, reduced polyp numbers in the small
intestine of mice.

Similarly, Cox-1 inhibition caused the same, suggesting that

mediators of inflammation are involved in tumor development 16,21,31.
Regulation of inflammation and cancer by IL-10
One distinct feature of mucosal immunity as it compares to nonmucosal forms
is that T cells of the gut have an activated or memory effector phenotype. They are
poised for rapid induction of inflammation via cytokine production when necessary, a
state that is tightly regulated by effector regulatory T cells in this environment that
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are poised to suppress inflammation.

These two mechanisms coexist, but the

immunological environment at mucosal surfaces tends to be a default program of
immunosuppression or tolerance. The T cells are designed to prevent active
inflammation in response to commensals, which continuously interact with the
surrounding epithelia32,33.
One cytokine identified to have anti-inflammatory properties is IL-10. IL-10deficient mice developed enterocolitis in the duodenum, jejunum, and colon,
characterized by significant growth retardation and ultimately death.

However, the

inflammatory conditions of the Il10 knockout mice were greatly attenuated when they
were housed under specific pathogen free conditions, suggesting that IL-10
suppresses the immune response to intestinal antigens

34

. Il10 receptor knockout

mice exhibited a similar phenotype, supporting the role of IL-10 in intestinal
homeostasis35.
Furthermore, Il10 knockout weanlings, the age where gastrointestinal normal
flora begin colonization, exhibited early signs of focal inflammatory lesions in the
intestine which progresses to transmural inflammation, epithelial hyperplasia and
then adenocarcinoma with age. Increased levels of proinflammatory cytokines, such
as TNF-α, IL-6, IL-1β and IFN-γ, were present in the colons of IL-10 deficient mice
as compared to wildtype mice. These sequelae were prevented in weanlings of Il10
knockout mice who were treated with IL-10 intraperitoneally. While IL-10 had no
statistically significant effect on the inflammation of adult mice, the IL-10 treatment
did reduce the incidence of adenocarcinoma36. These early findings suggest that IL-
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10 is required for maintaining intestinal homeostatic conditions and that its loss
promotes intestinal inflammation and colorectal cancer. Further observations that
colitis did not develop in IL-10-deficient mice treated with antibiotics or raised in a
germ free environment corroborated these conclusions, demonstrating the role of IL10 in suppressing immune cell reaction to intestinal microbiota37.
A study using Il10 green fluorescent protein (GFP) reporter mice
demonstrates that CD8+ intestinal epithelial lymphocytes (IELs) and CD4+
lymphocytes in the lamina propria cells are the major cells expressing IL-1038. In the
same study, in vivo stimulation of IELs from the small intestine with anti-CD3
demonstrated that these cells were programmed to be IL-10 producing cells.
Similarly, anti-CD3 stimulation of lamina propria lymphocytes induced a regulatory
phenotype where GFP expression was observed. Both Foxp3+ Treg cells and IL10-producing cells are responsible for homeostatic maintenance in the lamina
propria while Foxp3- IELs assume this role in the epithelium demonstrated by IL-10expressing GFP+ populations. Adoptive transfer of splenic CD4+ T cells to
immunodeficient mice demonstrated that the gut microenvironment contributes to
this phenotype where transferred cells found in the IEL compartment exhibited GFP
expression after stimulation while those recovered from the spleen did not38.
Furthermore, adoptive transfer of TCRαβ subpopulation of intestinal IEL into severe
combined immunodeficiency mice prior to the induction of chronic colitis
demonstrated that intestinal IELs suppress intestinal inflammation in an IL-10dependent manner39.
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TBK1 structure and regulation
The serine/threonine protein kinase TBK1 is involved in several signaling
pathways such as immune response to pathogen recognition, autophagy, cell
survival and growth and oncogenesis40.

Because of its molecular structure, its

ubiquitous expression pattern, TBK1 is thought to serve as an important signal
transducer, connecting various upstream signals to downstream biological
processes40. It possesses a catalytic kinase domain (KD) at its N-terminus that
interacts with its ubiquitin-like domain (ULD) and alpha helical scaffold dimerization
domain (SDD) (Figure 3)41,42.

Nearly full-length x-ray crystallography and TBK1

protein purification revealed that TBK1 exists in an homodimer conformation where
KD are outward on opposite sides of the complex in the inactive form41,42. KD and
SDD are conjugated with K63-linked ubiquitin chains at Lys 30 and Lys 401,
respectively, which is a necessary modification for its activation43. An x-ray crystal
structure from another group revealed that the KD of the active form of TBK1 is
repositioned to perform its catalytic functions while remaining in dimer formation and
keeping the C-terminus domain (CTD) facing away from the main body of the dimer.
This configuration also allows for trans autophosphorylation between TBK1 dimers,
resulting in phosphorylation of Ser172 in the activation loop of the KD domain41. In
addition to mediating homodimerization of TBK1, the SDD also is required for
substrate phosphorylation and has been speculated to facilitate adaptor protein
recruitment needed for regulating substrate specificity43,44. Dimerization is not
required, however, for adaptor protein interactions41. The CTD has been described
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as an adaptor-binding motif involved in the recruitment of TBK1 to various other
signaling mediators45. The adaptor-binding motif of TBK1 allows it to interact with a
variety partners to transduce a signal within a cell40. Furthermore, adaptor proteins
containing ubiquitin domains can bind to TBK1 via polyubiquitin chains, but the
specificity of TBK1 binding to its substrates is likely dependent upon its cellular
localization40,46. Cellular localization of TBK1 also regulates its activation by different
stimuli. In response to upstream signals, TBK1 is recruited, by adaptor proteins, to
specific signaling complexes, in which the concentrated TBK1 may be activated by
autophosphorylation or phosphorylation by upstream kinases40. TBK1 also contains
leucine zipper and helix-loop-helix motifs within the SDD region, although functions
of these motifs are less well defined45.
A major class of TBK1 stimuli is the pathogen-associated molecular patterns
(PAMPs), which are components of various microorganisms such as DNA, singleand double-stranded RNA, and surface glycoproteins. PAMPs initiate innate immune
responses through stimulation of pattern recognition receptors (PRRs). Several
PRRs are able to target the activation of TBK1 and induce type I interferon
production; these include the TRIF-dependent TLRs (TLR3 and TLR4), the NLR
member NOD2, the intracellular RNA sensor RIG-I, and the intracellular DNA sensor
STING. The activation and signaling function of TBK1 involve its recruitment to the
PRR adaptors, such as TRIF (TLR/IL-1R domain-containing adaptor protein inducing
IFN-β), MAVS (mitochondrial antiviral signaling proteins), and STING (stimulator of
IFN genes). Upon activation by the PRRs, TBK1 phosphorylates IRF3, triggering the
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dimerization and nuclear translocation of this anti-viral transcription factor and
allowing IRF3 to induce expression of the type I interferon genes (Figure 3)47. While
IRF3 is the most widely recognized substrate of TBK1, many others have been
identified, including the interferon-responsive transcription factor IRF7, NF-κB
members (p65 and c-Rel), signaling adaptors (TANK, MAVS, STING, and TRIF),
kinases (NIK, AKT, IKKα, IKKβ, and NEMO), E3 ubiquitin ligases (PELI1 and XIAP),
autophagy receptors (OPTN and p62), and the exocyst component Sec 5 in RalB
signaling40,48,49.
As seen with other kinases, TBK1 activation is subject to control by negative
regulators. One such TBK1 regulator is protein phosphatase Mg2+/Mn2+-dependent 1
B (PPM1B or PP2Cβ), which binds and dephosphorylates TBK1 at Ser172 and,
thereby, inhibits virus-induced IRF3 phosphorylation and IFN-β expression50.
Inositol 5’ phosphatase SHIP1 (Src homology 2 domain-containing protein tyrosine
phosphatase 1) has also been implicated as a negative regulator of TBK1; SHIP1
deficiency in macrophages resulted in hyperphosphorylation of TBK1 even under
unstimulated conditions and TLR3-stimulated IFN-β production51.

The authors

though did not present evidence describing the mechanism and therefore it remains
unknown whether SHIP1 directly or indirectly regulates TBK1 activity. Another
phosphatase, SHIP2, inhibits TBK1 activation and IFN-β production by directly
binding to the N terminal KD region of TBK1 and acting independently of the
phosphatase activity of SHIP252.
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As previously mentioned, ubiquitination of TBK1 plays an important role in its
activation. Ubiquitin ligase Nrdp1 directly binds and polyubiquitinates TBK1 in
macrophages after TLR stimulation, leading to IRF3 activation47. Conversely, the
function of TBK1 is negatively regulated by deubiquitinases, proteases that cleave
ubiquitin chains. The deubiquitinase CYLD has been shown to interact with TBK1
and removes K63-linked ubiquitin chains from it, resulting in reduced TBK1 kinase
activity and IRF3 phosphorylation as well as downregulated type I IFN
expression53,54. A20 is another deubiquitinase known to regulate TBK1 activation.
A20 functions as a ubiquitin-editing complex, composed of A20, Tax1 binding protein
1 (TAX1BP1), and A20 binding inhibitor of NF-κB 1 (ABIN1), which negatively
regulates TBK1 activation antiviral response by disrupting the association of TBK1
with its upstream activator TRAF347. A similar function has also been demonstrated
for the RING Finger Protein 11 (RNF11), which binds to TBK1 via TAX1BP1 and
inhibits TBK1 activation and virus-induced IFNβ expression by blocking the
association of TBK1 with TRAF3 and TBK1 K63 ubiquitination55.

TBK1 is also

negatively regulated through K48 type of ubiquitination, which targets TBK1 for
proteasomal degradation, an event typically observed at longer time points likely
involved in the resolution of a viral induced-inflammatory response.

E3 ligases

DTX4 and TRIP have been identified as mediators of this process47.
TBK1 as a mediator of multiple signaling pathways
TBK1, also termed T2K56 or NAK (NF-κB-activating kinase), was initially
identified in a two-hybrid screen as a protein that interacts with TANK, a regulator of
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NF-κB signaling pathway, and was proposed by Joel Pomerantz and David
Baltimore at that time to mediate TANK-dependent NF-κB activation18,57. Tbk1
deletion in mice results in embryonic death due to liver apoptosis and failure, a
phenotype similar to mice deficient in other mediators of the NF-κB signaling
pathway56,58. TBK1 was initially thought to serve as an upstream kinase of the
classical IkB kinase (IKK) IKKβ; however, later studies demonstrated a dispensable
role for TBK1 in the activation of IKK and NF-κB57,58. It is now clear that the
canonical function of TBK1 is to phosphorylate and activate IRF3, mediating type I
interferon induction during viral infection58. However, more recent studies have led to
the identification of additional targets of TBK1 in various other signaling pathways.
For example, TBK1 mediates CD40 and BAFF receptor-induced NIK degradation
and negatively controls noncanonical NF-κB activation, a function that is crucial for
maintaining normal production of the antibody IgA48. TBK1 also mediates proteolysis
of AKT and negatively regulates the activation of the metabolic kinase mTORC1 by
T-cell receptor, thereby modulating the activation and migration of T cells.59 In
cancer cells, TBK1 may play a role in mediating the expression of survival genes
through activation of NF-κB family members, such as c-Rel and p6545,60. It is
anticipated that additional signaling targets of TBK1 will be identified in normal and
cancer cells.
TBK1 in the regulation of immune responses
Although TBK1 is expressed ubiquitously in numerous cell types, much of
our knowledge about its functions comes from studies involving cells of the immune
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system. It is well supported by both in vitro and in vivo studies that activated TBK1
targets IRF3 and IRF7 for phosphorylation and activation in response to TLR or
nucleic acid sensor stimulation, resulting in the production of type I interferons
necessary for an antiviral response (Figure 4). TBK1-mediated IRF3 regulation is
also essential for preventing de novo viral replication in vivo58.
Using B cell-conditional Tbk1 knockout mice, our laboratory has revealed a
new role for TBK1 in negatively regulating IgA antibody class switching by targeting
the phosphorylation and degradation of NF-κB-inducing kinase (NIK), a key mediator
of the noncanonical NF-κB signaling pathway48. The B cell-conditional Tbk1
knockout mice had elevated levels of serum IgA and autoantibodies as well as
antibody deposition to the kidney glomeruli, associated with nephropathy-like
symptoms. Upon stimulation by some of the IgA inducers, such as stimuli of CD40
and BAFF receptor, the TBK1-deficient B cells have hyper-activation of noncanonical
NF-κB as a result of increased NIK protein level. Thus, TBK1 controls the fate of NIK
and the magnitude of noncanonical NF-κB activation in B cells to modulate antibody
responses48 (Figure 5).
TBK1 also plays a role in regulating T-cell activation and migration59. Mice
with T cell-specific Tbk1 ablation have increased frequency of T cells with activated
effector- or memory-like surface markers, indicative of aberrant activation under
homeostatic conditions. However, in a central nervous system (CNS) autoimmune
inflammation model, the TBK1-deficient effector T cells display a defect in migration
from the draining lymph nodes to CNS. Consequently, the T cell-conditional Tbk1
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knockout mice are refractory to the induction of experimental autoimmune
encephalomyelitis, an animal model for human multiple sclerosis. While previous
studies suggest a role for TBK1 in activating AKT via direct phosphorylation and
promoting human cancer cell survival49,61,62, genetic ablation of Tbk1 in T cells
unexpectedly causes enhanced activation of AKT and its downstream target
mTORC148,60,6159. It appears that TBK1-mediated AKT phosphorylation serves as a
trigger for AKT degradation (Figure 6). Ablation of one allele of Akt, to reduce its
level of expression in TBK1-deficient mice, restores the ability of their T cells to
migrate to CNS and renders them sensitive to EAE induction59.
TBK1 in autophagy
The process of autophagy occurs as a means to recycle damaged proteins or
cellular organelles in order to generate energy for the cell or to remove a molecular
threat during starvation states. Autophagy can also occur in response to microbial
infection as part of an innate immune response where an autophagosome forms
around the bacteria to prevent their replication and possibly induce their destruction.
This process involves ubiquitination of intracellular bacteria, a modification that
recruits the Ubiquitin-binding autophagic adaptor protein optineurin (OPTN) and,
thereby, triggers the assembly of the autophagic machinery. TBK1 has been
implicated as an important regulator of autophagy responses to bacterial infections,
in which TBK1 acts by phosphorylating OPTN and promoting its interaction with
autophagic components, particularly Atg863. Additional studies suggest that TBK1
also promotes the maturation of the autophagosome in macrophages during
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bacterial infection by phosphorylating the autophagy adaptor sequestosome 1 (also
called p62), which facilitates bacterial clearance32. These findings demonstrate
another mechanism of action for TBK1 in the regulation of immune responses.
TBK1 in oncogenesis
One of the first clues of TBK1’s potential involvement in cancer was
presented in 2006 by the groups of Ulrich Brinkmann and Ira Paston who performed
a high throughput screening using various cDNA expression libraries that revealed a
potential role for TBK1 and IRF3 in regulating angiogenesis64. Overexpression of
TBK1 or its target transcription factor IRF3 induce secreted factors that promote the
proliferation of human umbilical vein endothelial cells (HUVEC), a frequently used
marker for the study of angiogenesis. In line with this finding, TBK1 expression is
induced

under

hypoxic

conditions64,

a

physiological

state

within

tumor

microenvironment that promotes angiogenesis within solid tumors65. Some solid
tumors, such as human breast and colon cancer, have been shown to have
upregulated TBK1 expression, although the significance of this finding warrants
further studies since the data are quite variable among cancer patients64.
Shortly thereafter, Michael White’s group reported that TBK1 downregulation
by RNAi promotes apoptosis in HeLa, PANC-1 and MCF7 human cancer cell lines in
vitro through its activity downstream of the Ras-like protein RalB66. RalB, a kinase
implicated in tumorigenesis-associated processes45,67,68, can activate TBK1 in vitro,
signaling its interaction with downstream Sec proteins of the exocyst44,66,6766.

This

sequence of events is needed for the induction of oncogenic transformation by
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Ras45,66. Specifically, TBK1-deficient mouse embryonic fibroblast (MEF) cells could
not undergo transformation and eventually died after retroviral infection with mutant
KRASG12V as compared to wildtype MEFs that were transformed and grew in
culture66. A few years later, William Hahn and Tyler Jack’s group performed a screen
in 19 cell lines that possessed either KRAS wildtype or mutant gene using RNA
interference libraries targeting cell signaling mediators such as protein kinases,
phosphatases and oncogenes. The screen revealed TBK1 as a synthetic lethal
partner in KRAS mutant human lung cancer cell lines.

Specifically, this paper

showed that in vitro downregulation of TBK1 using short hairpin (sh) RNAs resulted
in decreased cell survival of lung cancer cells dependent upon KRAS. Additional
experiments from this paper showed that knockdown of TBK1 in KRAS mutant
human lung cancer cell lines resulted in decreased tumor size over time in xenograft
models using immunocompromised mice while human lung cancer lines exhibiting
wildtype KRAS exhibited either increase or no difference in xerograph tumor growth
after TBK1 downregulation as compared to mice injected with GFP shRNA control60.
The data from these high profile papers led to advanced studies in delineating
mechanisms by which TBK1 promotes survival in human cancer cell lines. Using in
vitro models, TBK1 was found to engage with and activate AKT after KRASG12V
transformation in a stimulant-dependent and -specific manner, thus promoting tumor
cell survival

62

. It has also been suggested that TBK1 promotes human lung cancer

cell survival through its regulation of autophagy, a cellular process that involves the
lysosomal degradation of intracellular organelles and proteins to generate
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macromolecules needed for cell survival and metabolism during starvation or to
maintain intracellular integrity of proteins and organelles for proper functioning69,70.
Similar to previous models, TBK1 knockdown in A549 human lung cancer cells using
RNA interference in vitro resulted in reduced punctate accumulation of microtubuleassociated protein 1B light chain 3 (LC3B), an autophagosomal indicator of
autophagy induction, which was associated with reduced nuclear translocation of
RelB using immunofluorescent imaging. The authors proposed a model that TBK1
participated in the autophagic process in KRAS mutant human lung cancer cells thus
leading to non-canonical NF-κB signal induction promoting cell survival or
proliferation69, although direct evidence is lacking for the latter. It is also remains
unclear how autophagy is directly regulated by TBK1 in this model.
With the use of quantitative mass spectrometry as an approach to study
protein phosphorylation, Eric Haura’s research team identified over 2000 alterations
in phosphorylation in nearly 400 proteins after TBK1 knockdown in human A549 lung
cancer cell line71.

From this large number, the authors focused on diminished

phosphorylation observed in the mitotic regulator polo-like kinase (PLK) 1 after TBK1
RNAi. In vitro assays demonstrated that TBK1 binds to and phosphorylates PLK1 at
Thr-210 during mitosis. In addition, the authors determined a correlation between
cell viability after TBK1 knockdown and cell viability after PLK1 pharmacological
inhibition71. While the authors independently confirmed previous reports that TBK1
knockdown in A549 cells reduces cell viability and separately demonstrated that
treatment of lung cancer cells in vitro with PLK1 inhibitors decreased cell survival, it
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remains to be determined whether TBK1-mediated PLK1 phosphorylation has a
direct link with cancer cell survival71.
While the study of the role of TBK1 in cancer has so far focused on KRASdependent lung cancer cells, a more recent work examined TBK1 using human
breast cancer cell lines and suggested the involvement of TBK1 in mediating breast
cancer resistance to tamoxifen treatment72.

TBK1 binds and phosphorylates

estrogen receptor alpha (ERα) at serine 305 in MCF7 breast cancer cell line, thereby
affecting ERα’s transcription activity. RNAi-mediated TBK1 silencing in MCF7 cells
results in slower growth of the cell line, whereas TBK1 overexpression in MCF7 cells
renders the cells more resistant to tamoxifen treatment.

Immunohistochemical

analyses revealed elevated expression of TBK1, as compared to normal tissue, and
positive correlation of TBK1 expression with the expression and Ser-305
phosphorylation of ERα. The higher TBK1 expression is also associated with poorer
disease-free survival in patients treated with tamoxifen, although this correlation is
not seen in patients who are not treated with tamoxifen. These findings suggest that
TBK1 may have a role in mediating breast cancer tamoxifen resistance72.
Despite the many studies that demonstrate the association of TBK1 with
cancer, a more recent work failed to demonstrate the requirement of TBK1 in cancer
cell survival by using large panel of human cancer cell lines and similar experimental
approaches employed by the others73. However, while the previous studies relied on
a single or limited number of TBK1 shRNAs, this later study used six different TBK1
shRNAs targeting different coding and 3’ untranslated regions. Although the TBK1
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shRNA used previously (shT17) did reduce the viability of cancer cells, many other
TBK1 shRNAs did not produce this phenotype, despite their high efficiency in TBK1
knockdown. Furthermore, overexpression of TBK1 in the shT17-knockdown cells
failed to rescue cell viability but restored the phosphorylation of IRF3, a primary
substrate of TBK173. These results suggest the possibility that some of the previous
observations may have been due to off-target effect of the TBK1 shRNAs.
Consistently, treatment of cancer cell lines with three different TBK1 inhibitors
efficiently inhibited IRF3 phosphorylation with only minimal effect on cell viability.
Moreover, no correlation could be demonstrated between the degree of Ras activity
in the cell lines and sensitivity to the inhibitors. Overall, the authors concluded that
the growth or survival of KRAS-dependent cancer cell lines is not entirely TBK1dependent73; thus creating controversy regarding this topic and raising the questions
of whether and how TBK1 regulates cancer development and whether its function
depends upon the type of tumor.
TBK1’s role in colon cancer is unknown
A prior study revealed that colon tumor samples taken from patients display
different patterns of TBK1 expression. Although some tumor samples have higher
levels of TBK1 expression than normal tissue, some other tumor samples have
greatly suppressed TBK1 expression64. These findings indicate the potential
involvement of TBK1 in CRC pathogenesis. Of note, TBK1 is localized to human
chromosome 12q14.174,75, a region associated with chromosomal abnormalities such
as deletions, inversions, duplications, insertions, and translocations in pancreatic,
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ovarian,

skin,

breast,

and

prostate

cancers

and

pulmonary

chondroid

hamartomas73,7476-78. Similarly, one report identified chromosome 12q14.1 copynumber losses in salivary duct carcinoma using a single-nucleotide polymorphism
microarray platform79. Of particular interest, putative shallow deletions and gains of
TBK1 accounted for 20 percent and 30 percent of adenocarcinoma tissue samples
sequenced from the large intestine of patients within validated and provisional
datasets of The Cancer Genomics Atlas (TCGA) respectively80,81 (Figure 7). The
datasets

are

made

publicly

available

through

TCGA

consortia

using

www.cbioportal.org that contain comprehensive large-scale genomic, transcriptomic
and epigenomic profiling of various cancers including colorectal cancer

80,81

. In

addition, point mutations were found in TBK1 in nearly two percent of patient
samples sequenced from adenocarcinoma tissues of the large intestine deposited in
Catalogue of Somatic Mutations in Cancer (COSMIC)

82,83

(Figure 3; Table 2).

These mutations were dispersed through all domains of TBK1 (Figure 3; Table 2), all
of which are necessary for its specific function41-43,84. Based on these findings, we
hypothesized that TBK1 might play a role in intestinal tumorigenic processes in vivo,
and we examined this hypothesis in this dissertation using a novel animal model.
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Figure 1. Multiple factors play a role in colorectal cancer development.
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Basement membrane (BM)
Various types of myeloid cells

Figure 1. Multiple factors play a role in colorectal cancer development.
As a result of some genetic and/or environmental changes including hereditary and
somatic mutations, injury and/or chronic inflammatory disease, aberrant crypt foci
(ACF) form and accumulate within the intestinal epithelium. As abnormal cell
signaling and diminished cellular protective functions such as DNA repair continues,
adenomas form. The disease advances to carcinoma when the adenomas invade
through the basement membrane (BM) into nearby tissues and lymph nodes. This
stage of development is driven by the accumulation of mutations and chromosomal
abnormalities and altered microenvironment. Advancement of the disease results in
malignancy whereby cancer cells metastasize into distant tissues, organs and lymph
nodes. Malignancy may result in death for patients with CRC.
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Figure 2. Disruption of the immunological balance in the gut contributes to
intestinal adenoma development.
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Basement membrane (BM)!
Various types of myeloid cells!

Figure 2. Disruption of the immunological balance in the gut contributes to
intestinal adenoma development. Illustration of the relationship between intestinal
tumorigenesis and inflammation. Disruption of intestinal epithelial cell homeostasis
during the initiation and progression of intestinal adenoma development alters the
behavior of intestinal immune cells, which influences disease progression.
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Figure 3. Structure of TBK1 indicating point mutations identified in
adenocarcinomas sampled from CRC patients.
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Figure 3. Structure of TBK1 indicating point mutations identified in
adenocarcinomas sampled from CRC patients.
Schematic of the structure of TBK1 indicating point mutations identified in almost two
percent of 1,226 CRC patient tumor samples sequenced from adenocarcinoma
tissues of the large intestine (deposited in Catalogue of Somatic Mutations in
Cancer). These mutations, including truncating mutations (*) and frame-shift (fs)
insertions and deletions (del), were located in the kinase domain (KD), ubiquitin-like
domain (ULD), the helical scaffold dimerization domain (SDD) and the C-terminal
domain (CTD), all of which are necessary for proper function of TBK1.
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Figure 4. TBK1 regulates type I interferon innate immune response.
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Figure 4. TBK1 regulates type I interferon innate immune response.
TBK1 mediates type I interferon expression upon PRR stimulation of innate immune
cells by phosphorylating transcription factor IRF3. This leads to subsequent nuclear
translocation dimerized IRF3 and activation of type I interferon gene expression.
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Figure 5. TBK1 negatively regulates noncanonical NF-κB signaling and IgA
production in B cells.
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Figure 5. TBK1 negatively regulates noncanonical NF-κB signaling and IgA
production in B cells.
In B cells, TBK1 negatively regulates IgA antibody class switching upon stimulation
of TACI or BAFF receptor. TBK1 controls B Cell antibody responses by targeting the
phosphorylation and degradation of NF-κB-inducing kinase (NIK), a key mediator of
the noncanonical NF-κB signaling pathway.
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Figure 6. TBK1 regulates T cell activation and egress from the lymph nodes by
regulating AKT.
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Figure 6. TBK1 regulates T cell activation and migration by regulating AKT.
In T cells, TBK1 regulates T cell activation and egress from lymph nodes to the
central nervous system under inflammatory conditions. The TBK1 controls T cell
migration from lymph nodes by targeting AKT for phosphorylation and degradation
thus regulating downstream mediators such as mTORC1 involved in T cell egress.
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Figure 7. Percentage of putative shallow deletion, diploid, gain and
amplification of TBK1 copy-number identified in adenocarcinomas sampled
from CRC patients profiled in validated and provisional datasets of TCGA.
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Figure 7. Percentage of putative shallow deletion, diploid, gain and
amplification of TBK1 copy-number identified in adenocarcinomas sampled
from CRC patients profiled in validated and provisional datasets of TCGA.
Putative shallow deletions gains of TBK1 accounted for 20 percent (top) and 30
percent (bottom) of adenocarcinoma tissue samples sequenced from the large
intestine of patients within validated (top) and provisional (bottom) datasets of The
Cancer Genomics Atlas (TCGA) respectively.

The datasets are made publicly

available through TCGA consortia using www.cbioportal.org.80,81
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CHAPTER 3: INTESTINAL EPITHELIAL CELL-SPECIFIC TBK1 INHIBITS
INTESTINAL ADENOMA GROWTH IN APCMIN/+ MICE
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Chapter 3: Intestinal epithelial cell-specific TBK1 inhibits intestinal adenoma
growth in Apcmin/+ mice
Introduction
Colorectal cancer (CRC) is a major cause of cancer morbidity and mortality
whereby almost 150,000 people are diagnosed per year and approximately one-third
of individuals will die from disease per year in the United States alone. Worldwide, it
affects almost 1.2 million people such that it is the third most common cancer
diagnosed in women and men2,85. Globally, almost 600,000 persons die from colon
cancer each year, which makes it one of the leading causes of cancer-related deaths
for men and women combined2. Since the prognosis of CRC is still poor, it is critical
to understand the process of intestinal tumor development and progression.
It is generally believed that CRC development results from dysregulated
signaling events in IECs, causing out-of-control growth and/or survival and
subsequent transformation of these cells. Several risk factors have been associated
with CRC, including somatic and germline mutations, chronic intestinal inflammation,
diet and lifestyle. For example, when the normal epithelium of the gut encounters
inflammation, environmental mutagens including reactive oxygen and nitrogen
species, tissue damage and repair, and/or inherited mutations within the intestine,
cellular signaling pathways are induced in order to maintain or return the gut to
homeostatic state. When these protective mechanisms are altered such that they do
not properly function, adenoma formation eventually may occur and pose the risk for
colorectal malignancies16,86. Understanding the biology and cellular mechanisms that
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are involved in this early stage process is important for improving the approaches for
CRC prevention and treatment.
The Wnt signaling pathway has been closely linked to the tumorigenic
process in the gut. A central regulator of the Wnt pathway is the tumor suppressor
adenomatous polyposis coli (APC), which functions by targeting the transcription
factor β-catenin for proteolysis. Abnormal activation of the Wnt signaling pathway
has been frequently observed in both hereditary and sporadic colorectal cancers and
is often attributed to the loss-of-function mutations of APC or activating mutations in
the transcription factor β-catenin87. A mouse model, Apcmin/+, has been frequently
used in the study of CRC. The Apcmin/+ mice carry a heterozygous mutation in the
Apc gene that leads to APC truncation19. This mouse model is particularly useful for
the identification of novel factors involved in the regulation of intestinal
tumorigenesis.
The serine/threonine protein kinase TBK1 is involved in several signaling
pathways such as pathogen recognition and immune response, inflammatory
response and Ras-dependent oncogenesis40. The current literature using human
lung and breast cancer cell lines implicates TBK1 as having oncogenic activity60,66,72.
Specifically, these in vitro studies and xenograft mouse models proposed that TBK1
supports cell survival of KRAS-driven lung cancers and tamoxifen-resistant breast
cancers60,66,72.

However, a more recent independent study challenged the

conclusions of these studies, stating that TBK1 is dispensable for cancer cell
survival73. The in vivo function of TBK1 in regulating intestinal tumorigenesis has not
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yet been explored. By generating intestinal epithelial cell (IEC)-conditional Tbk1
knockout mice, the present study addresses the role of TBK1 specifically in intestinal
tumor development. Our work unexpectedly demonstrated a role for TBK1 to
suppress intestinal tumorigenesis in the Apcmin/+ mice.
Results
IEC-specific Tbk1 ablation promotes adenoma formation in Apcmin/+ mice.
To study the role of TBK1 in the gut, we generated IEC-conditional Tbk1
knockout (hereafter called Tbk1IEC-KO) mice by crossing mice with Tbk1 loxP-flanked
(floxed) alleles with mice expressing Cre under the control of villin promoter (villinCre) (Figure 8A-C). Western blot demonstrates the loss of TBK1 protein from
isolated primary IECs in the Tbk1IEC-KO (Figure 8C). The Tbk1IEC-KO mice appeared
normal in growth and survival (data not shown). Based on gross examination, the
IEC-specific Tbk1 ablation did not appreciably alter the number (Figure 8A) or size of
Peyer’s patches in the small intestine. Histology analyses based on hemotoxylin and
eosin (H&E) staining also did not reveal noticeable inflammation or tissue damage in
the small intestines (Table 1) (Figure 9C and D).
We next crossed the Tbk1IEC-KO mice with the Apcmin/+ mice to examine the
role of TBK1 in regulating intestinal adenoma development (Figure 8D). Western blot
demonstrates the loss of TBK1 protein from isolated primary IECs in the
Apcmin/+Tbk1IEC-KO mice (Figure 8E). Loss of TBK1 in IECs of Apcmin/+ mice resulted
in increased polyp formation in the small intestines as compared to Apcmin/+ mice at
four months of age (Figure 10A-B, D). Such a phenotype was detected in both the
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distal and proximal regions of the small intestine of the Apcmin/+Tbk1IEC-KO mice,
although the distal region had a more profound increase in the number of polyps
(Figure 10B). These results suggest that the IEC-specific TBK1 plays a suppressive
role in intestinal tumorigenesis. In addition to polyp number, polyp size was larger in
Apcmin/+Tbk1IEC-KO mice compared to age-matched (four months) Apcmin/+ mice
(Figure 10C). The effect of TBK1 deficiency on adenoma size was observed mainly
in medium-sized adenomas. At an older age (six months), the Apcmin/+Tbk1IEC-KO
mice also formed large multifocal adenomas in the distal region of the small
intestine, which was not observed in the control Apcmin/+ mice (Figure 10E). These
findings suggest a role for the IEC-specific TBK1 in negatively regulating the
formation or growth of adenomas.
Since the distal region of small intestine, covering the ileum, has more
abundant Peyer’s patches and more diverse and abundant microbiota, we speculate
that the promotion of tumor growth in this region might be due to the inflammatory
nature of this environment, an idea which we are currently exploring.
Young Apcmin/+Tbk1IEC-KO mice exhibit earlier polyp formation as compared to
Apcmin/+ mice.
To assess the mechanism by which TBK1 regulates intestinal adenoma
formation, we examined whether the loss of TBK1 had an effect on the early stage of
polyp formation. We analyzed the polyps in young Apcmin/+ and Apcmin/+Tbk1IEC-KO
mice. Higher numbers of polyps were found in Apcmin/+Tbk1IEC-KO mice as early as six
weeks of age (Figure 11A). However, the TBK1 deficiency did not significantly alter
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the number of microadenomas (Figure 11B and C). Thus, it is likely that TBK1
regulates the growth, rather than initiation, of the intestinal adenomas in the Apcmin/+
mice.
TBK1 deficiency does not influence the proliferation of IECs or adenoma cells
To examine whether TBK1 regulates the proliferation of normal IECs or
adenoma cells, we performed in vivo cell proliferation assays based on
bromodeoxyuridine (BrdU) incorporation. Six-week old Apcmin/+ and Apcmin/+Tbk1IECKO

mice were injected with BrdU intraperitoneally, and BrdU incorporation was

assessed by immunohistochemical assays using an anti-BrdU antibody. We did not
observe obvious differences in BrdU incorporation in normal mucosa between the
Apcmin/+Tbk1IEC-KO and Apcmin/+ mice (Figure 11D-E). These animals also did not
show significant differences in BrdU incorporation within their microadenomas
(Figure 11F-G). In addition to BrdU incorporation, we examined the proliferative
effects of the TBK1 deficiency by immunocytochemistry staining with Ki67, a
commonly used indicator for cells in the state of proliferation. Immunohistochemical
analyses did not reveal appreciable differences in the frequency of Ki67+ cells in
either the normal tissue or larger adenomas between four month old Apcmin/+ and
Apcmin/+Tbk1IEC-KO mice (Figure 12A-C).
TBK1 deficiency likely promotes cell survival of intestinal microadenomas
We examined the role of TBK1 in regulating apoptosis using a TUNEL assay
that detects fragmented DNA in apoptotic cells. Analyses of the Apcmin/+ and
Apcmin/+Tbk1IEC-KO intestinal tissues did not reveal major differences in the frequency
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of TUNEL positive apoptotic cells in the normal mucosa (Figure 13A-B).
Interestingly,

analyses

of

TUNEL

positive

cells

in

microadenomas

from

Apcmin/+Tbk1IEC-KO intestinal tissues revealed a trend toward enhanced cell survival
as compared to Apcmin/+ mice (Figure 13C-D). Because we did not achieve statistical
significance with p = 0.07 (Figure 13D) using the arbitrary threshold of p < 0.05, we
can not exclude the possibility that the observed difference may be due to chance.
However, if we test with a less stringent threshold of 10 percent significance, then
the difference of TUNEL positive cell frequency between the microadenomas in
Apcmin/+ and Apcmin/+Tbk1IEC-KO may achieve statistical significance. Additionally, if
we consider the 90 percent confidence intervals of 2.5 to 0.13 for these data, then it
is likely that IEC-specific Tbk1 deletion promotes cell survival in microdadenomas in
Apcmin/+ mice. Further analyses are needed to make more solid conclusions.
Additional sections of microadenomas will be analyzed to increase the number of
observations per group.

Furthermore, given that IEC-specific Tbk1 ablation

promotes enlargement in medium-sized tumors, we will assess the apoptotic indexes
of medium sized tumors from Apcmin/+ and Apcmin/+Tbk1IEC-KO.
IEC-specific Tbk1 ablation does not cause visible intestinal inflammation
Recent findings have revealed a complex relationship between inflammation
and cancer, suggesting that the immune response can both suppress and promote
tumor development16,88. More recently, intestinal chronic inflammatory diseases have
been identified as a risk factor for colon cancer89,90. Under normal conditions, the
immune system does not mount strong responses to commensal microbes, which is
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important for the maintenance of intestinal immune homeostasis and prevention of
inflammation. Impaired barrier function or innate immune function in intestinal
epithelia may cause bacterial invasion and chronic inflammation. Since TBK1 has
been implicated in the regulation of innate immunity and inflammatory processes40,72,
we examined whether Tbk1 ablation in IECs might impair immune homeostasis and
cause intestinal inflammation.
To determine if TBK1 in IECs plays a role in immune homeostasis in the gut,
we sacrificed wildtype and Tbk1IEC-KO mice and resected the colons and small
intestines to count the number of Peyer’s patches in the small intestine. Both the
small intestine and colons were formalin-fixed, cut and H&E stained. We examined
the colonic tissues and counted the number of colonic lymphoid follicles visible in
two bi-level sections of swiss-rolled tissues. We observed no significant difference
in the number of Peyer’s patches nor colonic patches between Tbk1 wildtype and
Tbk1IEC-KO mice (Figure 9A-B). With the assistance of a pathologist, we blindly
scored the tissues based on the presence of immune cells within the mucosa,
submucosa, and/or transmural and on the extent of the mucosal damage (Table 1).
We observed no overt histological difference in inflammation between Tbk1 wildtype
and Tbk1IEC-KO mice (Figure 9C-D).

These data suggest that IEC-specific Tbk1

deletion alone in the IECs does not impair immune homeostasis nor lead to
spontaneous inflammation in the gut.
Intestinal tumorigenesis may be promoted by altered production of proversus anti-inflammatory cytokines without overt histological inflammation91.
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Therefore, we tested whether the TBK1 deficiency caused low-grade inflammation
within the intestine by analyzing gene expression of inflammatory mediators using
real-time quantitative PCR (qPCR). We detected the expression of pro- and antiinflammatory cytokines, chemokines and cell markers such as Tnfα, Il1β, Il17a, Il17f,
Il10, Il12p35, Ccl2, Cox2, Foxp3, Tgfβ, and interferons (IFNs) including Ifnα, β and γ
by performing qPCR. These inflammatory mediators have previously been identified
to play a role in tumor development. There was no detection of significant difference
in any of these inflammatory proteins in Tbk1IEC-KO as compared to wildtype mice
(Figure 14). Taken together, these data suggest that Tbk1 deletion alone in IECs
does not appreciably alter inflammatory environment in the gut nor does it
spontaneously induce polyp formation even after aging the mice for one year (Figure
9D).
Tbk1 ablation in IECs does not promote inflammation or adenoma formation in
a chemically induced colitis-associated tumor model.
Severe colitis can be induced by interrupting the epithelial barrier using
chemicals, such as dextran sodium sulfate (DSS). The DSS-induced colitis has been
frequently used for the study of inflammation and inflammation-associated cancer.
DSS damages the colonic epithelial cell barrier thus inducing an immune response to
the colonic microbes mediated by innate immune cells70. We treated Tbk1IEC-KO and
wildtype mice with DDS for either five or seven days with two-day water recovery
period (Figure 15A). The mice were weighed once per day during this treatment
period and sacrificed at day two after DSS treatment. We observed no difference in
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the weight or the histological score between wildtype and Tbk1IEC-KO. Both groups of
mice exhibited similar levels of decreased weight loss and colonic inflammation after
treatment (Figure 15B-F).
To test the role of IEC-specific TBK1 in colitis-associated colon cancer, we
treated wildtype and Tbk1IEC-KO mice with a single dose of azoxymethane (AOM), a
genotoxic colon carcinogen, and several cycles of DSS and water92 (Figure 16A).
Consistent with the results obtained in mice treated with DSS alone, the IEC-specific
TBK1 deficiency did not alter the level of inflammation in mice treated with DSS
along with AOM, as shown by the similar level of bodyweight loss and colon
shortening in the wildtype and Tbk1IEC-KO mice (Figure 16B and D). We also
observed no difference in the number of polyps formed in the colons of wildtype and
Tbk1IEC-KO mice (Figure 16C). Therefore, we hypothesize that TBK1 functions in
IECs through another mechanism, possibly by modulating the adaptive immune cell
component in the intestines. It is also possible that in our model, TBK1 in IECs may
exert its functions in the context of Apc mutations.
The effect of TBK1 deficiency on adenoma formation is diminished in the
absence of lymphocytes
To examine the role of adaptive immune system in regulating adenoma
formation in Apcmin/+ and Apcmin/+Tbk1IEC-KO mice, we crossed these mice with Rag1
knockout mice lacking mature T and B lymphocytes, key cellular mediators of the
adaptive immune system93. We crossed Apcmin/+ Tbk1 IEC mouse model with Rag1
knockout mice. The small intestines of the mice were resected, fixed and counted for
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number of polyps at age 2.5-3 months. As expected, Apcmin/+Tbk1IEC-KO mice had a
substantially higher number of polyps than Apcmin/+ Tbk1 mice under lymphocytecompetent conditions (Figure 17). When crossed to the Rag1 knockout background,
the number of polyps was greatly enhanced in both Apcmin/+Tbk1IEC-KO and Apcmin/+
mice (Figure 17), likely due to the loss of the immunosuppressive Treg cells and/or
IELs38, 39. Moreover, under these lymphocyte-free conditions, the TBK1 deficiency
only had a moderate, and statistically insignificant, effect on polyp formation.
The results described above suggest that TBK1 may regulate an aspect of
adaptive immune homeostasis that is masked by the loss of Treg and other
lymphocytes in the Rag1 knockout conditions. We first examined the effect of TBK1
on immune homeostasis by analyzing the intestinal immune cell composition,
specifically lymphocytes in addition to innate immune cells. We resected the small
intestines of young mice and isolated both intestinal IELs and the lamina propria
cells94. The Apcmin/+Tbk1IEC-KO and Apcmin/+ mice had a comparable frequency of
TCRβ+ or γδTCR+ T cells (Figure 18 A-B; Figure 19 A-B) and myeloid CD11c+
and/or CD11b+ cells (Figure 18 C-D) in either the lamina propria or IEL
compartments of the small intestine. The expression levels of Foxp3, a marker for
Treg cells, were also similar between Apcmin/+Tbk1IEC-KO and Apcmin/+ mice (Figure
18E). These results suggest that loss of TBK1 in IECs does not alter the immune
cell composition in the intestinal tissue, raising the question of whether the TBK1
deficiency may cause abnormal function of the intestinal lymphocytes.
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TBK1 deficiency in the IECs of Apcmin/+ mice inhibits Il10 production in the
intestine
Although IEC-specific Tbk1 deletion alone does not alter the expression of
cytokines in the intestine (Figure 14), it remains possible that TBK1 plays a role in
regulating cytokine protein in the context of Apc mutation. This possibility was
suggested by the profound effect of TBK1 deficiency on adenoma formation in the
Apcmin/+ mice. We therefore tested Apcmin/+ mice the effect of TBK1 deficiency in IECs
on the expression of various cytokines and chemokines involved in the inflammatory
process and cancer (Figure 20A). Because of the crucial role of TBK1 in regulating
type I interferon induction, we also included interferon-responsive genes, such as
Il10, Cxcl11, Cxcl9, Cxcl10, and Irf7, which have been shown to be effected by the
loss of TBK1 in innate immune cells. In addition, we examined the β-catenin target
genes Axin2 and Lgr5, to assess the possible role of IEC-specific TBK1 in regulating
Wnt signaling pathway, as well as genes involved in host defense (Reg3β and
muc2). We quantitatively analyzed the expression of these genes from intestinal
tissues of young 3.5-4 week old Apcmin/+ and Apcmin/+ Tbk1IEC-KO mice presumably
before microscopic adenoma formation. Interestingly, the IEC-specific TBK1
deficiency in Apcmin/+ mice significantly inhibited the gene expression of the antiinflammatory cytokine Il10 in the intestine, although the expression of the rest of the
genes was comparable between the Apcmin/+ and Apcmin/+ Tbk1IEC-KO mice (Figure
20A). Il10 expression levels are sustained in mice after sole IEC-specific deletion of
Tbk1 or sole Apcmin/+ genotype (Figure 20B). Given the crucial role for IL-10 in
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suppressing intestinal tumorigenesis, this finding provides important insights into the
mechanism by which TBK1 regulates adenoma formation in the Apcmin/+ mice.
IEC-specific TBK1 regulates IL-10 production by IELs
As mentioned in Chapter 2, IECs can secrete cytokines and chemokines to
initiate a mucosal immune response upon detection of commensal and pathogenic
antigens, guiding homeostasis within the environment14. While there is little evidence
of IECs expression of Il10 in vivo, it has been shown that human IECs can produce
this anti-inflammatory cytokine in vitro95,96. In addition, IECs may stimulate IL-10
production by macrophages and lymphocytes, but the underlying mechanism has
not been defined97. A large source of IL-10 in the intestine is produced by the IELs,
although some cell types of the lamina propria (e.g. macrophages, dendritic cells,
and regulatory T cells) can also produce IL-1012,38. In fact, intestinal IELs suppress
chronic intestinal inflammation in an IL-10-dependent manner.39

Therefore,

analyzed Il10 expression in highly purified IECs, intestinal epithelial lymphocytes,
and lamina propria cells of the Apcmin/+ and Apcmin/+ Tbk1IEC-KO mice. To our surprise,
the IEC-specific Tbk1 knockout did not affect Il10 expression in the IECs but
impaired the Il10 expression in IELs (Figure 21A-B). This effect was specific, since
the TBK1 deficiency did not affect Il10 expression in the lamina propria cells (Figure
21C). This finding supports the previous in vitro finding that IECs stimulate IL-10
production in lymphocytes and establishes TBK1 as an important factor mediating
this crosstalk in vivo.
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Discussion
The data presented in this study show that TBK1 functions in IECs to inhibit
intestinal adenoma growth in Apcmin/+ mice. Loss of TBK1 in IECs of Apcmin/+ mice
resulted in increased polyp formation in the small intestines, a phenotype observed
as early as six weeks of age. The increase in polyp number in the Apcmin/+Tbk1IEC-KO
mice was seen in both the proximal and distal regions of small intestine, but this
phenotype was more pronounced in the distal region. Polyp size was greater in the
Apcmin/+Tbk1IEC-KO mice as compared to Apcmin/+ mice, specifically in the medium
sized adenomas.
TBK1 has previously been shown to be important in regulating the immune
response by mediating type I interferon production, IgA production, and T cell
activation and migration48,59,98. In addition, previous in vitro studies using human lung
and

breast

cancer

cell

lines

implicate

TBK1

to

have

tumor-promoting

activity45,60,62,66,72. TBK1 knockdown promotes apoptosis and reduces xenograft
tumor growth of KRAS-dependent lung cancer cells but not of KRAS-independent
tumor cell lines60. TBK1 appears to also contribute to the resistance of breast cancer
cells to tamoxifen resistance72. However, a more recent publication challenged some
of these findings and suggest that some of the phenotypes of TBK1 knockdown
cancer cell lines may be due to off-target effect of the TBK1 shRNAs73. In addition to
the controversy, the previous work also had several limitations in addressing the
cancer-regulatory function of TBK1. First, the use of mouse xenograft models, which
rely on immunodeficient recipient mice, excludes the contribution of immune system,
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a major component of the tumor microenvironment that regulates tumor growth and
progression. Second, since human cell lines often have accumulated genetic
alterations, the cell line studies cannot assess the role of TBK1 in regulating the
early-stages of tumorigenesis. Furthermore, the use of shRNA-mediated knockdown
approach or pharmacological inhibitors of TBK1 have the issue of specificity due to
off-target effect shRNAs and pharmacological inhibitors. Our conditional Tbk1 KO
mouse model allowed us to study the in vivo role of TBK1 during the early stages of
intestinal tumorigenesis in immunocompetent mice. With our new approach, we
discovered an unexpected function of TBK1 in suppressing the formation of intestinal
adenoma, an early stage of CRC development.
Within the mucosa, IELs, predominately CD8+ T cells, are interspersed
throughout and in direct contact with the epithelial cell layer; this puts them along
with the IECs at the forefront of the intestinal immune response. As part of the
mucosa, the lamina propria, which lies beneath a basal membrane under the IEC
and IEL layers, defines a compartment for heavily infused circulating immune cells
particularly T lymphocytes including effector T cells and Treg cells, macrophages,
plasma cells, eosinophils, and mast cells. The IECs can express immunological
mediators to help guide the appropriate response to commensal microbes or
pathogens, a delicate balance required to achieve homeostasis within the
environment14. We found that TBK1 in IECs function to regulate Il10 expression in
IELs to produce IL-10 during the early stages of the tumorigenic process, which is
illustrated in a schematic in Figure 22. Previous studies showed that IL-10-deficient
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mice developed enterocolitis in the duodenum, jejunum, and colon and that Il10
knockout weanlings, the age where gastrointestinal normal flora begin colonization,
exhibited early signs of focal inflammatory lesions in the intestine which progresses
to transmural inflammation, epithelial hyperplasia and then adenocarcinoma with
age34,36. Higher levels of proinflammatory cytokines such as TNF-α, IL-6, IL-1β and
IFN-γ were present in the colons of IL-10-deficient mice as compared to wildtype
control mice. These sequelae were prevented in weanlings of Il10 knockout mice
when treated with IL-10 intraperitoneally such that the incidence of adenocarcinoma
in these mice was reduced36. These early findings suggest that IL-10 is required for
maintaining intestinal homeostatic conditions and its loss can lead to intestinal
inflammatory disease and colorectal cancer. Impaired IL-10 production in the
intestine is also linked to enhanced intestinal tumorigenesis in other knockout mouse
models crossed with the Apcmin/+ mice91. Thus, our finding that TBK1 deficiency in
IECs inhibits IL-10 production provides mechanistic insight into the role of TBK1 in
regulating intestinal adenoma formation.
We demonstrated that the tumor-regulating function of TBK1 is diminished
when the Apcmin/+Tbk1IEC-KO mice were crossed to the lymphocyte-deficient Rag1
knockout background. Under these conditions, the number of polyps was greatly
increased in both the Apcmin/+ and Apcmin/+Tbk1IEC-KO mice. Since Rag1 knockout
mice lack both conventional T cells and Treg cells, it is likely that the lack of
immunosuppressive Treg cells may contribute to an inflammatory environment that
promotes tumor formation33-86. Indeed, transfer of wildtype Treg cells into the Apcmin/+
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mice reduces tumor burden24. More importantly, the tumor-suppressing function of
Treg cells requires their production of the immunosuppressive cytokine IL-1024. Of
note, intestinal IELs suppress intestinal inflammation in an IL-10-dependent
manner39. Our finding that TBK1 regulates Il10 expression in the intestine thus has
important implications. Although TBK1 does not seem to regulate Il10 expression in
Treg cells, the IEC-specific TBK1 is required for IL-10 production by another major
source of IL-10 producing cells, the IELs. Additional studies are required to elucidate
the mechanism underlying this novel and intriguing function of TBK1. One
hypothesis is that TBK1 may regulate the production of a secreted factor(s) in IECs,
which in turn stimulate the IELs for IL-10 expression.
Clinical Importance
As previously mentioned in Chapter 2, the localization of human chromosome
12q14.1, the region where TBK1 lies, is associated with chromosomal abnormalities
in cancers including in pancreatic, ovarian, skin, breast, prostate, and salivary duct
cancers and pulmonary chondroid hamartomas74-79. Of particular interest, shallow
deletions and gains of TBK1 accounted for 20 percent and 30 percent of
adenocarcinoma tissue samples sequenced from the large intestine of patients
within validated and provisional (Figure 7) datasets of The Cancer Genomics Atlas
(TCGA)

respectively.

Publicly

available

through

TCGA

consortia

using

www.cbioportal.org, these datasets contain comprehensive large-scale genomic,
transcriptomic and epigenomic profiling of various cancers including colorectal
cancer

80,81

. The copy numbers of TBK1 significantly correlated with TBK1 mRNA
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expression in these samples (Figure 23A), where TBK1 mRNA expression
significantly decreased or increased in samples with putative shallow deletions or
gains as compared to diploid TBK1 copy-number respectively (Figure 23B).
However, neither TBK1 copy number nor mRNA expression levels significantly
correlated with the overall survival of these patients (Figure 24). However, analysis
of TBK1 mRNA expression levels within different stages of colorectal cancer, from
stage I through stage IV, revealed a significant correlation between TBK1 mRNA
expression in tumors sampled during stage IIIC and the overall survival of those
patients (Figure 25 A-B). During stage IIIC of disease, the cancer has grown through
the outer layers of the intestine into the visceral peritoneum and has spread to
nearby lymph nodes but has not yet reached nearby tissues or distant organs99. In
addition, a moderately high correlation existed between TBK1 mRNA expression in
tumors during early stage of disease to TBK1 mRNA expression in tumors during
later stages (Figure 25 C), suggesting a strong relationship between the degree to
which TBK1 is expressed in early staged tumors and in later stages as the cancer
progresses.
Further analyses using these profiles were performed to determine the clinical
relevance for the role of TBK1 in colon cancer. Similar to the trends found with TBK1
mRNA expression using TCGA data were trends found with expression of APC,
TP53, KRAS, and PIK3CA genes (Figure 26), well-known regulators of the
tumorigenic process17,30,87,100,101.

In fact, APC, TP53, KRAS, and PIK3CA are

among the top five most frequently mutated genes, with a frequency of mutation at
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61 percent, 43 percent, 34 percent, and 16 percent respectively in the validated
dataset of TCGA (Figure 26A). Although copy numbers of these genes - APC,
TP53, KRAS, and PIK3CA - significantly correlated with its respective mRNA
expression (Figure 26B) as did TBK1 copy number and its mRNA expression (Figure
23A), no correlations were found between the copy number (Figure 27A) or mRNA
expression levels (Figure 27B) of either gene and the overall survival of the patients
as observed with TBK1 and overall survival irrespective of disease stage (Figure
24). This suggest that the correlation between patient overall survival and gene
expression of recurrently mutated genes may not be sufficient to predict its role in
cancer development.
As an important signal transducer in various downstream biological
processes, TBK1 function is dependent upon its molecular structure as well as its
expression pattern40.

Interestingly, point mutations in TBK1 were found in

approximately two percent of the large intestinal genomic profiles from 1,226 patient
tumor samples deposited in Catalogue of Somatic Mutations in Cancer
(COSMIC)82,83.

Twenty-two different TBK1 mutations (Table 2) in these patient

samples included missense, nonsense and synonymous substitutions as well as
frame-shift deletion and insertion, and in-frame deletion and were relatively
dispersed throughout the KD, ULD, SDD and CTD of TBK1 with missense mutations
accounting for the majority (Table 2; Figure 3; Figure 28). Mutationassessor.org
software offered by cBio@MSKCC uses evolutionary conservation patterns of intraand interspecies homologues in families and sub-families empirically to predict the
impact of amino acid substitutions on protein function. With this software, functional
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impact scores are calculated using multiple sequence alignments, with the
assumption that protein function is likely affected by specific substitutions of
conserved residues102.

To predict the functional impact of the missense TBK1

mutations listed in Table 2, each mutation was assessed using the algorithm
provided. Only two of the 14 missense mutations were classified as a “medium” level
of functional impact, predicting that these mutations may alter the function of TBK1
(Table 2).

Both of these mutations, F56C and A188V, were localized within the

catalytic and activation loops of the KD of TBK1 respectively.

A change in

conserved residues within these loops could potentially alter the function of TBK1
since the structural configuration of these loops within the KD influence the activation
state of TBK141. Experimental validation is needed to test this prediction.
Almost half of missense mutations found in TBK1 were given a “low” score for
functional impact, predicting that these specific mutations would have no influence
on TBK1 function (Table 2). These mutations were primarily localized within the
ULD and SDD of TBK1.

Each domain of TBK1 influences its context-specific

function41-43,84. Particularly, the ULD of TBK1 interacts with its own KD and SDD and
is required for the full activity of TBK1 KD; this is critical for the regulation of IFNinducible gene transcription during an immune response42,84. Furthermore, the ULD
and KD of TBK1 interact with the SDD of the other TBK1 subunit in the dimer, while
the CTD serves as a binding site for several adaptor proteins involved in TBK1mediated signal transduction41-43,103.

These intricacies in the structure of TBK1

become particularly important as we determine the functional implications for TBK1
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sequence alterations revealed in the TCGA and COSMIC databases. For example,
mutationassessor.org predicted that E355K substitution would not influence the
function of TBK1 (Table 2). However, E355 is a key residue at the ULD interface
that

participates

in

TBK1

homodimerization.

TBK1

E355A,

R357D,

and

E355A/R357D double mutations disrupted the activation of TBK1 and downstream
signaling events, which diminished TLR-induced type I interferon gene expression in
vitro

43

. These findings support the need for experimental validation of all predicted

outcomes of amino acid substitutions determined by mutationassessor.org, including
TBK1 E355K.

While mutationassessor.org is limited to predicting the effect of

missense mutations, one could predict that nonsense mutations such as TBK1
R357* found in the COSMIC database (Table 2) may alter the activity of TBK1 given
that R357D mutation impaired its function and truncation within the ULD would likely
alter TBK1 homodimerization, activation and substrate specificity 41-43,84.
The molecular structure, the subcellular localization, the specificity of binding
partners and substrates, and the expression pattern directs the activity of TBK1 in
various cellular processes40. Further analyses of colorectal cancer patient profiles
from TCGA using www.cbioportal.org indicated a strong relationship between the
expression of TBK1 and other well-known factors involved in colorectal cancer
initiation and progression, including APC, KRAS, and PIK3CA (Figure 29). TBK1
mRNA expression highly and significantly correlated with the APC, KRAS and
PIK3CA mRNA expression - three of the top five genes most frequently mutated in
colorectal cancer patient samples (Figure 26A). Our in vivo model presented earlier
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in this chapter revealed that TBK1 functions in IECs to inhibit intestinal adenoma
growth in Apcmin/+ mice (Figure 10), a model of early staged disease19. Our Tbk1 IEC
conditional knockout model provides a mechanism that explains the strong positive
association between TBK1 and APC gene expression gleaned from the
transcriptomic profiles from TCGA (Figure 29).

A significantly strong positive

association also existed between TBK1 and KRAS and TBK1 and PIK3CA gene
expression. The question still remains whether TBK1 negatively regulates intestinal
adenoma growth in KRAS or PIK3CA mutant backgrounds. Furthermore, TCGA
patient sample data revealed a positive correlation between the mRNA expression of
TBK1 and IL10 (Figure 30), which is consistent with the results of our in vivo model
where IEC-specific deletion of Tbk1 diminished Il10 expression in the intestine.
Taken together, these data support the clinical relevance of our model, providing a
mechanism for the link between APC, TBK1 and IL-10 during intestinal adenoma
development.
The findings presented in this chapter illustrate the role of TBK1 during early
stage develop of intestinal adenomas.

Because TBK1 currently serves as an

attractive target in the discovery of anti-inflammatory and anti-cancer therapeutics
where its pharmacological inhibitors are now readily available, the findings of the
present study could have significant impact in the field. It suggests the need for
careful consideration regarding the context in which TBK1 functions, which would
ultimately aide in the selection of treatment modalities and preventative strategies for
patients and influence the outcomes of treatments used to target this protein kinase.
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My project studies suggest a need for careful consideration in the selection of
treatment modalities targeting TBK1 in cancer patients of other tissue types as it is
possible that long term use of TBK1 inhibitor could possible increase the risk for
adenoma growth in the intestine.
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Figure 8. Generation of intestinal epithelial cell conditional Tbk1 mouse
model.
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Figure 8. Generation of intestinal epithelial cell conditional Tbk1 and Apcmin/+
Tbk1 mice. Conventional Tbk1 KO mice are embryonic lethal56; therefore, to
address our hypothesis, we generated Tbk1 intestinal epithelial cell-conditional KO
(Tbk1IEC-KO) mice by crossing Tbk1 floxed mice with villin-Cre mice. A) Schematic
image of Tbk1 gene targeting in IECs. Two loxP sites were inserted adjacent to
coding exon. Deleted allele depicts the removal of exon 2 after villin-Cre-mediated
loxP recombination. B) PCR was used to detect the Tbk1 floxed and wildtype alleles
and cre transgene in tail DNA. The +/+ Cre+ are indicated as Tbk1 wildtype while fl/fl
Cre+ are indicated as Tbk1IEC-KO. C) Western blot was used to detect TBK1 protein
levels from isolated primary IECs of the mice. D) IEC-conditional Tbk1 mice were
crossed with Apcmin/+ mice to generate well-known Apcmin/+ colon cancer model.
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Figure 9. Tbk1IEC-KO mice have normal development and intestinal
homeostasis. IEC-specific ablation of Tbk1 does not induce spontaneous
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Figure

9.

Tbk1IEC-KO

mice

have

normal

development

and

intestinal

homeostasis. IEC-specific ablation of Tbk1 does not induce spontaneous
tumor formation as mice age. After sacrificing 13 week old mice, small intestines
and colons were resected. A) Peyer’s patches in the small intestine were identified
grossly and counted. Data presented as the mean ± SD. (n=2 wildtype; n=4 Tbk1IECKO

) B) Colonic patches were identified histologically and counted. Data presented as

the mean ± SD. (n=2 wildtype; n=4 Tbk1IEC-KO) C) Small intestines were formalinfixed and histologically scored (based on inflammation extent and mucosal damage
in Table 1) to determine alterations in tissue morphology. Data presented as the
mean ± SD. (n=2 wildtype; n=4 Tbk1IEC-KO) D) Representative image of H&E stained
tissue section of wildtype and Tbk1IEC-KO small intestines at one year of age. (n=3
wildtype; n=4 Tbk1IEC-KO)
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Figure 10. IEC-specific TBK1 ablation greatly promotes adenoma development
in Apcmin/+ mice.
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Figure 10. IEC-specific TBK1 ablation greatly promotes adenoma formation in
Apcmin/+ mice.

A) Representative images of tumor development in the small

intestines of Apcmin/+ and Apcmin/+Tbk1IEC-KO mice at four months of age. B) Polyp
numbers in the entire small intestine, distal region (13cm from the caecum) and
proximal regions. C) Summary of tumor sizes in the entire small intestine. D) H&E
staining of the distal region of the small intestine showing increased adenomas in
Tbk1IEC-KO mice at four months of age. E) Representative picture of large multifocal
adenomas in the distal region of the small intestine from the Apcmin/+Tbk1IEC-KO mice
at six months of age. Each symbol in the graphs represents an individual mouse.
The data are presented as mean ± SEM. The symbol * represents p < 0.05 and **
represents p < 0.01.
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Figure 11. TBK1 deficiency in IECs promotes polyp formation in young mice
min/+

YoungApc
APCmin/+ mice.
TBK1 IEC-KO mice exhibit early polyp formation as compared
to APCmin/+ TBK1 WT mice; however, there is no significant difference between
groups in microadenoma formation.!
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Figure 11. Young Apcmin/+Tbk1IEC-KO mice exhibit earlier polyp formation as
compared to Apcmin/+ mice. A) Polyp (gross macroadenoma) numbers in the entire
small intestine at six weeks of age. B) Microadenoma numbers in the entire small
intestine histologically-identified (tri-level) at six weeks of age. C) Representative
images of histologically-identified microadenomas of the small intestines of Apcmin/+
and Apcmin/+Tbk1IEC-KO mice at six weeks of age. D) Representative images of BrdU
immunohistochemical staining of the normal mucosa in the small intestines of
Apcmin/+ and Apcmin/+Tbk1IEC-KO mice at six weeks of age. E) Enumeration of the of
BrdU+ cells per crypt within the normal mucosa of the small intestines of Apcmin/+ and
Apcmin/+Tbk1IEC-KO mice at six weeks of age. F) Percentage of BrdU positive (+) cells
per microadenoma determined as the percentage of BrdU+ nuclei per DAPI stained
nuclei per microadenoma. All microadenomas identified per swiss-rolled intestinal
tissue section were analyzed. The data are presented as mean ± SEM values (n= 5
Apcmin/+ mice; n=7 Apcmin/+Tbk1IEC-KO mice. Each symbol in the graphs represents an
individual mouse. The symbol * represents p < 0.05.
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Figure 12. IEC-specific TBK1 ablation does not influence the proliferation of
IECs or adenoma cells in older Apcmin/+ mice.
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Figure 12. IEC-specific TBK1 ablation does not influence the proliferation of
IECs or adenoma cells in older Apcmin/+ mice. A) Representative images of Ki67
immunohistochemical staining of the normal mucosa of the small intestines of
Apcmin/+ and Apcmin/+Tbk1IEC-KO mice at four months of age. B) Representative
images of Ki67 immunohistochemical staining of the adenomas in the small
intestines of Apcmin/+ and Apcmin/+Tbk1IEC-KO mice at four months of age. C)
Enumeration of the percentage of Ki67 + cells per field of view for the large
adenomas in the small intestines of Apcmin/+ and Apcmin/+Tbk1IEC-KO mice at four
months of age.
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Figure 13. IEC-specfic-TBK1 deficiency promotes cell survival in the intestinal
microadenomas
of Apcmin/+ mice.
min/+

Young APC
TBK1 IEC-KO mice exhibit trend of less TUNEL positive cells as
compared to APCmin/+ mice; however, statistical significance not achieved.!
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Figure 13. IEC-specfic-TBK1 deficiency likely promotes cell survival in the
intestinal microadenomas of Apcmin/+ mice. A) Representative images of TUNEL
fluorescent and DAPI staining of the normal mucosa of the small intestines of
Apcmin/+ and Apcmin/+Tbk1IEC-KO mice at six weeks of age. B) Percentage of TUNEL
positive (+) cells per villus determined as the percentage of GFP positive nuclei per
DAPI positive nuclei per villus. Graph presents mean ± SEM values (n=3 mice per
genotype; at least 6-9 images of different intestinal tissue focal areas were analyzed
per mouse counting cells of at least 6-7 villi per area). C) Representative images of
TUNEL fluorescent and DAPI staining of microadenomas of the small intestines of
Apcmin/+ and Apcmin/+Tbk1IEC-KO mice at six weeks of age. D) Percentage of TUNEL
positive cells per microadenoma determined as the percentage of GFP positive
nuclei per DAPI positive nuclei per microadenoma. Graph presents mean ± SEM
values (n= 6 Apcmin/+ mice; n=5 Apcmin/+Tbk1IEC-KO mice; p=0.071; 90% CI = 2.45,
0.135). Each symbol in the graph represents mean percentage of an individual
mouse. All microadenomas identified per swiss-rolled intestinal tissue section were
analyzed.
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Table 1. Histological colitis and small intestinal inflammation scoring method.
Supplemental Figure. !

Table 1!
A. Histological Colitis Scoring Method (modified from K. Williams et. Al, Gastroenterology (2001))!
Feature scored
!
!
!
! Score
!
!Description !!
Inflammation extent!
!
!
!
!0
!
!none !!
!
!
!
!
!1
!
!mucosa!
!
!
!
!
!2
!
!mucosa and submucosa!
!
!
!
!
!
!
!3
!
!transmural!
Mucosal damage !
!
!
!
!0
!
!none !!
!
!
!
!
!
!
!0
!
!intraepithelial neutrophils and crypt abscess!
!
!
!
!
!
!
!1
!
!crypts lost; surface epithelium present!
!
!
!2
!focal ulcers present (cypts and surface epithelium lost)!
!
!
!
!
!
!
!3
!
!diffuse/extensive ulcer!
!
B. Small intestine histological scoring method (Modified from Gomes-Santos et. al; Clinical and Developmental Immunology (2012) !
Feature scored
!
!
!
!
Score !
!Description!
extent of damage to mucosal architecture
!0
!
!normal !
1
!
!mild !
2
!
!moderate!
3
!
!extensive !
degree of cellular infiltration
!
!
!0
!
!normal !
1
!
!mild !
2
!
!moderate!
3
!
!transmural!
extent of muscle thickening
!
!
!0
!
!normal !
1
!
!mild !
2
!
!moderate!
3
!
!extensive !
crypt abscesses
!
!
!
!
!0
!
!absent !
1
!
!present!
loss of goblet cells !
!
!
!
!0
!
!absent !
1
!
!present!
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Table 1. Histological colitis and small intestinal inflammation scoring method.
Tissue sections from either the colon or the small intestine of Tbk1IEC-KO and wildtype
mice were H&E stained and blindly scored based on the presence of immune cells
within the mucosa, submucosa, and/or transmural and on the extent of the mucosal
damage.
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Figure 14. Tbk1 deletion in IECs does not alter the expression of
inflammatory mediators in the gut.
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Figure 14.

Tbk1 deletion in IECs does not alter the expression of

inflammatory mediators in the gut. qPCR analysis of indicated genes using the
distal small intestines (13cm from caecum) wildtype or Tbk1IEC-KO mice. Normalized
expression levels were calculated relative to the expression of internal control Actb.
Data are presented as mean ± SEM based on multiple samples and representative
of one experiment. Each symbol represents a mouse.
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Figure 15. Tbk1 ablation in IECs does not promote inflammation in a
chemically induced colitis model.
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Figure 15. Tbk1 ablation in IECs does not promote inflammation in a
chemically induced colitis model. A) Schematic of treatment with DSS for five or
seven days followed by two-day recovery with water before sacrificing Tbk1IEC-KO
and wildtype mice. B) Tbk1IEC-KO and wildtype mice were weighed each day during
3.5% DSS treatment for seven days followed by two day recovery with water. Data
presented as mean change in weight ± SD as percentage (n=5 per genotype). C)
After treatment and recovery, colons were resected, formalin-fixed, H&E stained and
histologically scored for evidence of inflammation (based on inflammation extent and
mucosal damage in Table 1). Data presented as the mean ± SD (n=5 each group).
D) Representative H&E stained colonic tissue section from mice treated with 3.5%
DSS for seven days. The extent of tissue damage in both groups was similar in
tissue sections from mice treated with 3% DSS (data not shown). E) Tbk1IEC-KO and
wildtype mice were weighed each day during 3.0% DSS treatment for five days
followed by two day recovery with water. Data presented as mean change in weight
± SD as percentage (n=5 per genotype).

89

Azoxymethane,(AOM)and,DSS4induced,inﬂamma9on4
associated,carcinogen4induced,colorectal,cancer,model,
• Administra9on,of,DSS,for,several,cycles,(e.g.,,5,days,DSS,,14,days,
Figure 16. Tbk1 ablation in IECs does not promote inflammation or adenoma
water),results,in,chronic,coli9s,
formation a chemically induced colitis-associated tumor model.
– If,combined,with,a,single,ini9al,dose,of,the,genotoxic,colon,
carcinogen,azoxymethane,(AOM),!,inﬂamma9on4associated,
colorectal,cancer,(Tanaka,,T.,et,al.,Cancer'Sci.'2003)'
B

Day,0,

Day,5,

H20,

Day,19, Day,24,

H20,

Day,38, Day,43,

2.5%,DSS,

2.5%,DSS,

H20,

2.5%,DSS,

Day,57,

10

D

11

Colon
length (cm) !
colon length (cm)

6
4
2
0

10
9
8
7
6

Tbk1+/+! Tbk1 IEC-KO!

K1

IE

C-

TB
K1

KO

W
T

Tbk1 IEC-KO!

TB

W
T

Tbk1+/+!

Tbk1 IEC-KO!

Males and females - colon length

8

TB
K1

(colon)

C

Number of polyps/mouse
Polyp
Number (colon)!

Males and Females

Tbk1+/+!

IE
CKO

Ongoing,,

Sacriﬁce,and,
examine,
tumor,
forma9on,

Change in weight (g)!

10mg/kg,AOM,

AOM i.p. – 3 cycles of 2% DSS/H20!

TB
K1

A

1 AOM injection-3 rounds DSS/water

90

Figure 16. Tbk1 ablation in IECs does not promote inflammation or adenoma
formation a chemically induced colitis-associated tumor model. A) Schematic
of treatment with a single dose of azoxymethane (AOM) followed by three cycles of
DSS and water before sacrificing Tbk1IEC-KO and wildtype mice. B) Tbk1IEC-KO and
wildtype mice were weighed as indicated during treatment. Data presented as mean
± SD (n=9 wildtype; n=7 Tbk1IEC-KO). C) After three cycles of DSS/water treatments,
colons were resected and measured for length. Data presented as mean ± SEM. D)
Colons were formalin-fixed and number size of gross polyps was determined. Data
presented as mean ± SEM. Each symbol in the graphs (C and D) represents an
individual mouse.
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Figure 17. The effect of TBK1 deficiency on adenoma formation is diminished
in the absence of lymphocytes.
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Figure 17. The effect of TBK1 deficiency on adenoma formation is diminished
in the absence of lymphocytes. Gross adenomas in the entire small intestine 2.5
to 3 months old Apcmin/+ Rag1 knockout and Apcmin/+Tbk1IEC-KO Rag1 knockout mice
were counted. The data are presented as mean ± SD (n=3 for Apcmin/+ Rag1
knockout mice and n=2 for Apcmin/+Tbk1IEC-KO Rag1 knockout mice).
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Figure 18. IEC-specific Tbk1 ablation in Apcmin/+ mice does not alter the
frequency of immune cell composition in intestinal lamina propria.
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Figure 18. IEC-specific Tbk1 ablation in Apcmin/+ mice does not alter the
frequency of immune cell composition in intestinal lamina propria. A) Flow
cytometric analysis of CD45+ subpopulations of αβ T cells (TCRβ+) or γδ T cells
(TCRγδ+) from the lamina propria of Apcmin/+ and Apcmin/+Tbk1IEC-KO mice distal small
intestines at three and one-half to four weeks old. Data are presented as a
representative dot plot with each quadrant indicating the percentage of cells among
total CD45+ cells. B) Summary graphs of mean ± SEM of lamina propria
subpopulations of ab T cells and gd T cells based on two independent experiments.
Each symbol represents a mouse. Data represent two independent experiments. C)
Flow cytometric analysis of CD45+ myeloid populations of CD11chi/int/- and/or
CD11bhi/int/- cells from the lamina propria of Apcmin/+ and Apcmin/+Tbk1IEC-KO mice distal
small intestines at three and one-half to four weeks old. Data are presented as a
representative dot plot with each quadrant indicating the percentage of cells among
total CD45+ cells. D) Summary graphs of mean ± SEM of lamina propria
subpopulations of CD11chi/int/- and/or CD11bhi/int/- myeloid cells based on two
independent experiments. Each symbol represents a mouse. Data represent two
independent experiments. E) Distal small intestinal (SI) tissues were analyzed for
Foxp3 mRNA expression using qPCR. Normalized expression levels were calculated
relative to the expression of internal control Actb. Data are presented as mean ±
SEM based on multiple samples and representative of one experiment. Each symbol
represents a mouse.
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Figure 19. Tbk1 ablation in IECs of Apcmin/+ mice does not alter the frequency
of IEL subpopulations of αβ or γδ T cells in the small intestine.
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Figure 19. Tbk1 ablation in IECs of Apcmin/+ mice does not alter the frequency
of IEL subpopulations of αβ or γδ T cells in the small intestine. Flow cytometric
analysis of CD45+ IEL subpopulations of αβ T cells (TCRβ+) or γδ T cells (TCRγδ+)
from the small intestines of Apcmin/+ and Apcmin/+Tbk1IEC-KO mice at three and one-half
to four weeks old. A) Data are presented as a representative dot plot with each
quadrant indicating the percentage of cells among total CD45+ cells. B) Summary
graphs of mean ± SEM of IEL subpopulations of ab T cells and gd T cells based on
two independent experiments. Each symbol represents a mouse. Data represent
two independent experiments.
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Figure 20. TBK1 deficiency in IECs leads to defective IL10 expression in
Apcmin/+ mice small intestines.
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Figure 20. TBK1 deficiency in IECs leads to defective IL10 expression in the
intestines of Apcmin/+ mice. qPCR analysis of indicated genes using the distal small
intestines (13cm from caecum) from A) Apcmin/+ and Apcmin/+Tbk1IEC-KO mice or B)
wildtype, Tbk1IEC-KO, Apcmin/+ and Apcmin/+Tbk1IEC-KO mice. Normalized expression
levels were calculated relative to the expression of internal control Actb. Data are
presented as mean ± SEM based on multiple samples and are representative
graphs of two independent experiments. Each symbol represents a mouse. The
symbol * represents p < 0.05.
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Figure 21. Loss of TBK1 in IECs results in diminished levels of IL10
expression by intestinal IELs Apcmin/+ mice.
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Figure 21.

Loss of TBK1 in IECs results in diminished levels of IL10

expression by intestinal IELs Apcmin/+ mice. qPCR analysis of IL10 mRNA
expression using A) primary IECs, B) primary IELs, or C) primary immune cells from
the lamina propria (LP) of distal the small intestines from Apcmin/+ and
Apcmin/+Tbk1IEC-KO mice. Normalized expression levels were calculated relative to the
expression of internal control Actb. Data are presented as mean ± SEM based on
multiple samples and are representative graphs of two independent experiments.
Each symbol represents a mouse. The symbol * represents p < 0.05.
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Figure 22. A schematic representing our proposed model of IEC-specific TBK1
regulation of intestinal adenoma growth in vivo.

Proposed Model!
1!

A!

2!

3!

Normal!
LUMEN!

TBK1!

present'
in'
IECs'

Microadenoma!

IEL!

IEL!

5!

Adenoma!

IEC!

IEC!

TBK1!

TBK1!

IEC!

TBK1!

4!

growth!

IEL!

BM!

IL-10!

IL-10!

IL-10!
LAMINA
PROPRIA!

2! a)
b)

APC LOH initiates tumorigenic process.!
Production of inflammatory mediators dysregulates.!

c) IELs maintain IL-10 expression.!
4! Apoptosis initiates.!

Inflammatory mediators!

B!

1!

2!

3!

4!

5!

Increased
adenoma growth!

Increased!
microadenoma!
growth!

Normal!
TBK1!
LUMEN!

IEC!

IEC!
IEL!

IEL!

absent'
in'
IECs'

BM!

IL-10!

IL-10!

growth!

IEL!

IEC!

IL-10!

LAMINA
PROPRIA!

2! a)
b)

APC LOH initiates tumorigenic process.!
Production of inflammatory mediators dysregulates.!

c) IEL expression of IL-10 diminishes.!
4! Microadenoma cells survive.!

Inflammatory mediators!

102

Figure 22. A schematic representing our proposed model of IEC-specific TBK1
regulation of intestinal adenoma growth in vivo. A) Under normal conditions,
intestinal homeostasis is maintained with IECs forming a single-layer barrier
between the lumen and lamina propria. Abnormal loss-of-heterozygosity (LOH) of
tumor suppressor APC triggers deregulated cellular signaling and inflammation
leading

to

microadenoma

microadenoma

to

formation.

macroadenoma

TBK1

growth

in
by

IECs

negatively

maintaining

the

regulates
levels

of

immunosuppressive cytokine IL-10 produced by intestinal IELs during the
tumorigenic process, resulting in apoptosis of adenoma cells. B) However, upon
initiation of the adenoma formation in the absence of TBK1 in IECs, intestinal IELs
express diminished levels of Il10. With continued aberrant cell signaling and
inflammation after LOH of Apc, the absence of TBK1 in IECs promotes intestinal
adenoma growth through increased adenoma cell survival.
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Figure 23. Copy numbers of TBK1 significantly correlated with TBK1 mRNA
expression in colorectal adenocarcinoma samples deposited in TCGA.
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Figure 23. Copy numbers of TBK1 significantly correlated with TBK1 mRNA
expression in colorectal adenocarcinoma samples deposited in TCGA.
Copy number and mRNA expression data were collected using the RNASeqV2 data
from validated (n=227) and provisional (n=375) genomic and transcriptomic profiles
of colorectal adenocarcinoma tumor samples in TCGA at www.cbioportal.org74. (A)
The correlation between copy numbers of TBK1 and TBK1 mRNA expression in
colorectal adenocarcinoma samples deposited in TCGA. (B) TBK1 mRNA
expression in samples with putative shallow deletions, diploid, gains or amplification
with n for each group as indicated on graph. One-way ANOVA with Tukey’s multiple
comparisons test was used to analyze mean differences in mRNA expression levels
between groups of putative copy-number alternations with the exception of the
putative amplification group (n=1).

Data presented as mean ± 95% confidence

intervals with alpha of 0.05. p-values of <0.05, <0.01, <0.001, <0.0001 correspond
with (*), (**), (***), and (***) annotations respectively.
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Figure 24. TBK1 copy number or mRNA expression in colorectal
adenocarcinoma samples deposited in TCGA did not correlate with overall
survival of patients.
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Figure 24.

TBK1 copy number or mRNA expression in colorectal

adenocarcinoma samples deposited in TCGA did not correlate with overall
survival of patients.
Overall patient survival data, TBK1 copy number, and TBK1 mRNA expression data
were collected using the RNASeqV2 data from validated (n=227) and provisional
(n=375) genetic profiles of colorectal adenocarcinoma tumor samples in TCGA at
www.cbioportal.org74. (A) The correlation between copy numbers of TBK1 in
colorectal adenocarcinoma samples in TCGA and overall survival (months) of
patients. (B) The correlation between copy numbers of TBK1 mRNA expression in
colorectal adenocarcinoma samples and overall survival (months) of patients.

The

Pearson correlation test was used to examine correlation using data from the TCGA
validated and provisional datasets. p-values of <0.05, <0.01, <0.001, <0.0001
correspond with (*), (**), (***), and (***) annotations respectively.
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Figure 25. TBK1 mRNA expression in colorectal adenocarcinoma samples
from disease stage IIIC correlate with survival of patients; correlation exists
between levels of TBK1 mRNA expression in samples from early and late
stage of disease.
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Figure 25.

TBK1 mRNA expression levels in colorectal adenocarcinoma

samples from disease stage IIIC correlate with survival of patients; correlation
exists between levels of TBK1 mRNA expression in samples from early and
late stage of disease.
Overall patient survival data and TBK1 mRNA expression data were collected using
the RNASeqV2 data from validated and/or provisional) genetic profiles of colorectal
adenocarcinoma tumor samples in TCGA at www.cbioportal.org74. (A) The
correlation between mRNA expression of TBK1 in colorectal adenocarcinoma
samples in TCGA during each disease stage from validated dataset (n=241) and
overall survival (months) of those patients. The Pearson correlation test was used to
examine correlation with n for each stage as indicated on graph. (B) The correlation
between mRNA expression of TBK1 in colorectal adenocarcinoma samples in TCGA
during each disease stage from provisional dataset (n=347) and overall survival
(months) of those patients. The Pearson correlation test was used to examine
correlation with n for each stage as indicated on graph. (C) Box and whisker plot of
TBK1 mRNA expression in samples from disease stage I through stage IV from
validated dataset (top) (n=241) and provisional dataset (n=347) (bottom).

The

Pearson correlation test was used to examine correlation between stages of
disease. p-values of <0.05, <0.01, <0.001, <0.0001 correspond with (*), (**), (***),
and (***) annotations respectively.
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Figure 26. APC, TP53, KRAS, and PIK3CA are among the top five most
frequently mutated genes in colorectal adenocarcinomas. APC, TP53, KRAS,
and PIK3CA mRNA expression correlates with copy number of its respective
gene.
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Figure 26.

APC, TP53, KRAS, and PIK3CA are among the top five most

frequently mutated genes in colorectal adenocarcinomas. APC, TP53, KRAS,
and PIK3CA mRNA expression correlates with copy number of its respective
gene. (A) Frequency of mutation in APC, TP53, KRAS, SYNE1 and PIK3CA in the
colorectal adenocarcinoma validated dataset of TCGA.

(B) Correlation between

copy numbers of APC, TP53, KRAS, SYNE1 and PIK3CA and its respective mRNA
expression in the colorectal adenocarcinoma validated dataset (n=227) of TCGA .
mRNA expression data were collected using the RNASeqV2 data, frequency of
mutation, and copy number are data from validated and/or provisional genetic
profiles

of

colorectal

adenocarcinoma

tumor

samples

in

TCGA.

www.cbioportal.org74. The Pearson correlation test was used to examine correlation
between stages of disease. p-values of <0.05, <0.01, <0.001, <0.0001 correspond
with (*), (**), (***), and (***) annotations respectively.
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Figure 27. No correlation between overall survival of patients and APC, TP53,
KRAS, SYNE1 and PIK3CA copy number or mRNA expression in colorectal
tcga validated data - TP53 cna correlation months survival

tcga validated data - KRAS cna correlation months survival

tcga
validated data - APC cnasamples
correlation months
adenocarcinoma
fromsurvival
validated

TCGA validated dataset!

p = 0.5541

1.5

TP53 log2 copy-number

1.0
0.5
0.0
-0.5

p = 0.7646

1.0
0.5
0.0
-0.5

TCGA validated dataset!
KRAS
log2copy
copy-number
KRAS
log2
number!

TCGA validated dataset!
PIK3CA log2 copy-number
PIK3CA log2 copy number! TP53 log2 copy number!

log2 copy-number
APCAPC
log2
copy number!

A

TCGA dataset.

p = 0.7454

4
3
2
1
0
-1

-1.0
tcga validated
data - 20
SYNE1 cna
correlation
months
survivaldata - PIK3CA cna correlation months survival
tcga80validated
40
60
-1.5

Overall Survival (Months)

SYNE1
log2 copy number!
SYNE1 log2 copy-number

Overall Survival (Months)!

1.5

TCGA validated dataset!

p = 0.9779

1.0
0.5
0.0
-0.5
-1.0

20

40

60

80

Overall Survival (Months)
Overall
Survival (Months)!

-1.0
-1.5

1.5

20

40

60

80

Overall Survival (Months)

Overall Survival (Months)!

-2

20

40

60

80

Overall Survival (Months)

Overall Survival (Months)!

TCGA validated dataset!

p = 0.0596

1.0
0.5
0.0
-0.5
-1.0

20

40

60

80

Overall Survival (Months)
Overall
Survival (Months)!

tcga validated data - KRAS correlation months survival

TP53%mRNA%expression

3
2
1
0

0

20

40

60

Overall Survival (Months)

80

250

p = 0.2699

200
150
100
50
0

0

20

40

60

KRAS%mRNA%expression
KRAS
mRNA expression!

p = 0.3526

80

p = 0.2714
20

10

0

0

20

tcga validated data - SYNE1 correlation
months
survival
tcga
validated
data - PIK3CA correlation months survival
15

TCGA validated dataset!

p = 0.2824
10

5

0

0

20

40

60

Overall
Survival (Months)
Overall
Survival
(Months)!

80

TCGA validated dataset!

8

p = 0.2764

6
4
2
0

0

20

40

60

Overall Survival (Months)

Overall Survival (Months)!

114

40

60

Overall
Survival (Months)
Overall
Survival
(Months)!

Overall
Survival (Months)
Overall
Survival
(Months)!

Overall Survival (Months)!

PIK3CA
lmRNA expression!
PIK3CA'mRNA'expression

mRNA
expression
mRNA
expression!
SYNE1
mRNA expression! APCAPC
SYNE1&mRNA&expression&

4

TP53 mRNA expression!

tcga validated data - APC correlation months
survival
tcga validated
data - TP53 correlation months survival
TCGA validated dataset!
TCGA validated dataset!
30 TCGA validated dataset!
B

80

80

Figure 27. No correlation between overall survival of patients and APC, TP53,
KRAS, SYNE1 and PIK3CA copy number or mRNA expression in colorectal
adenocarcinoma samples from validated TCGA dataset.
(A) Correlation between APC, TP53, KRAS, SYNE1 and PIK3CA copy number in
colorectal adenocarcinoma samples from validated TCGA dataset (n=255) and
overall survival (months) of patients. (B) Correlation between mRNA expression of
APC, TP53, KRAS, SYNE1 and PIK3CA in colorectal adenocarcinoma samples from
validated TCGA dataset (n=242) and overall survival of patients (months). mRNA
expression data were collected using the RNASeqV2 data, copy number and overall
survival are data from validated genetic profiles of colorectal adenocarcinoma tumor
samples in TCGA. www.cbioportal.org74. The Pearson correlation test was used to
examine correlation between stages of disease. p-values of <0.05, <0.01, <0.001,
<0.0001 correspond with (*), (**), (***), and (***) annotations respectively.
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Figure 28. Percentages of different types of TBK1 mutations found in the
large intestine of patient colorectal adenocarcinoma samples (COSMIC and

COSMIC
data
- types
ofmutations
mutations
pie
Types of
TBK1 point
found in
thechart
large intestine of patient samples (COSMIC and TCGA datab
TCGA database).

63.64% Substitution missense
13.64% Substitution synonymous
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4.55% Insertion frameshift
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4.55% Deletion frameshift

Total = 22
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Figure 28. Percentages of different types of TBK1 point mutations found in
the large intestine of patient colorectal adenocarcinoma samples (COSMIC
and TCGA database).
Pie chart indicating the percentages of different types of point mutations identified in
CRC patient tumor samples (excludes cultured cell line data) sequenced from
adenocarcinoma tissues of the large intestine deposited in Catalogue of Somatic
Mutations in Cancer (COSMIC) and The Cancer Genome Atlas (TCGA) including
missense, nonsense, and synonomous mutations as well as insertion and deletion
frame-shifts deletion in-frame-shift.

Total of 22 mutations were found in these

databases.

117

Table 2. Description and location of the point mutations found in the large
intestine of patient tumor samples (COSMIC and TCGA database) with
predicted functional impact determined by mutationassessor.org.
Point mutation! Tissue site!

Type!

Functional ! Functional !
impact level! impact score! Database!
TCGA validated!
Medium!
2.785!
TCGA validated!
Low!
1.245!

TBK1 F56C!

Colon!

Missense!

TBK1 S347Y!

Colon!

Missense!

TBK1 S632L!

Colon!

Missense!

Neutral!

0.55!

TBK1 T389I!

Colon!

Missense!

Neutral!

0.46!

TBK1 R357*!

Colon!

Nonsense!

N/A!

N/A!

TCGA validated!
TCGA validated!
TCGA validated!

TBK1 A188V!

Colon!

Missense!

Medium!

2.41!

COSMIC!

TBK1 A535T!

Colon!

Missense!

Neutral!

-0.805!

COSMIC!

TBK1 D720Y!

Colon!

Missense!

Low!

0.805!

COSMIC!

TBK1 E355K!

Colon!

Missense!

Low!

1.1!

COSMIC!

TBK1 L366L!

Synonymous!

N/A!

N/A!

COSMIC!

TBK1 L366V!

Rectum!
Large
intestine!

Missense!

Low!

0.805!

COSMIC!

TBK1 M263V!

Colon!

Missense!

Neutral!

-0.025!

COSMIC!

TBK1 Q289R!

Colon!

Missense!

Low!

1.22!

COSMIC!

TBK1 R574G!

Colon!

Missense!

Low!

0.975!

COSMIC!

TBK1 R724C!

Colon!

Missense!

Neutral!

0!

COSMIC!

TBK1 T599T!

Caecum!

Synonymous!

N/A!

N/A!

COSMIC!

TBK1 T651T!

Colon!

Synonymous!

N/A!

N/A!

COSMIC!

TBK1 V275D!

Colon!

Missense!

Neutral!

-2.66!

COSMIC!

TBK1 R440*!

Colon!

N/A!

N/A!

COSMIC!

TBK1 E643delE!

Colon!

N/A!

N/A!

COSMIC!

TBK1 L658fs*23!

Colon!

Nonsense!
Deletion
inframe!
Deletion
frameshift!

N/A!

N/A!

COSMIC!

TBK1 I397fs*5!

Caecum!

Insertion
frameshift!

N/A!

N/A!

COSMIC!
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Region of mutation!
Protein kinase domain !
(p. 9 - 307)!
Ubiquitin-like domain !
(p. 309 - 384)!
Potential coiled domain !
(p. 626 - 713); !
Helical scaffold dimerization domain !
(p. 408 - 654)!
Near ubiquitin-like domain !
(p. 309 - 384)!
Ubiquitin-like domain !
(p. 309 - 384)!
Protein kinase domain !
(p. 9 - 307)!
Helical scaffold dimerization domain !
(p. 408 - 654)!
C-terminal domain!
(p. 658 - 745)!
Ubiquitin-like domain !
(p. 309 - 384)!
Ubiquitin-like domain !
(p. 309 - 384)!
Ubiquitin-like domain!
(p. 309 - 384)!
Protein kinase domain !
(p. 9 - 307)!
Protein kinase domain !
(p. 9 - 307)!
Helical scaffold dimerization domain !
(p. 408 - 654)!
C-terminal domain !
(p. 658 - 745)!
Helical scaffold dimerization domain !
(p. 408 - 654)!
Potential coiled domain !
(p. 626 - 713); !
Helical scaffold dimerization domain !
(p. 408 - 654)!
Protein kinase domain !
(p. 9 - 307)!
Helical scaffold dimerization domain !
(p. 408 - 654)!
Helical scaffold dimerization domain !
(p. 408 - 654)!
C-terminal domain!
(p. 658 - 745)!
Near ubiquitin-like domain !
(p. 309 - 384); !
Near helical scaffold dimerization domain !
(p. 408 - 654)!

Table 2. Description and location of the point mutations found in the large
intestine of patient tumor samples (COSMIC and TCGA database) with
predicted functional impact determined by mutationassessor.org.

To predict the functional impact of the missense TBK1 mutations listed in Table 2,
each mutation was assessed using the software application at mutationasessor.org.
Functional impact scores were calculated using the algorithm provided by
mutationassessor.org, which is based on scores using multiple sequence alignments
with an assumption that protein function is likely affected by specific substitutions of
conserved residues. A “neutral” or “low” score for functional impact predicts that a
specific mutation would have no influence on the function of the protein of interest
whereas a “medium” or “high” score predicts that the mutation likely may alter the
function of the protein102.
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Figure 29. APC, KRAS, and PIK3CA mRNA expression correlates with TBK1
mRNA expression in colorectal adenocarcinomas sampled from TCGA.
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Figure 29. APC, KRAS, and PIK3CA mRNA expression correlates with TBK1
mRNA expression in colorectal adenocarcinomas sampled from TCGA.
Correlation between TBK1 mRNA expression and mRNA expression of APC, TP53,
KRAS, SYNE1 and PIK3CA in the validated dataset (n=244) of TCGA.

mRNA

expression data were collected using the RNASeqV2 data are from validated genetic
profiles

of

colorectal

adenocarcinoma

tumor

samples

in

TCGA

at

www.cbioportal.org74. The Pearson correlation test was used to examine correlation
between stages of disease. p-values of <0.05, <0.01, <0.001, <0.0001 correspond
with (*), (**), (***), and (***) annotations respectively.
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Figure 30. IL10 mRNA expression correlates with TBK1 mRNA expression in
colorectal adenocarcinomas sampled from TCGA.
TBK1 mRNA and IL10 mRNA correlation TCGA validated
TBK1 mRNA and IL10 mRNA correlation TCGA provisional all
TCGA validated dataset!
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Figure 30. IL10 mRNA expression correlates with TBK1 mRNA expression in
colorectal adenocarcinomas sampled from TCGA. Correlation between TBK1
mRNA expression and IL10 mRNA expression in the validated and provisional
dataset of TCGA. mRNA expression data were collected using the RNASeqV2 data
are from validated (n=244) and provisional (n=382) genetic profiles of colorectal
adenocarcinoma tumor samples in TCGA at www.cbioportal.org74.

The Pearson

correlation test was used to examine correlation between stages of disease. pvalues of <0.05, <0.01, <0.001, <0.0001 correspond with (*), (**), (***), and (***)
annotations respectively.
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CHAPTER 4: INVESTIGATING THE ROLE OF TBK1 IN HUMAN COLORECTAL
CANCER CELLS
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Chapter 4: Investigating the role of TBK1 in human colorectal cancer cells
Introduction
As discussed in previous chapters, TBK1 is involved in several signaling
pathways such as pathogen recognition and immune response, inflammatory
response and oncogenesis40. In particular, several reports have implicated TBK1 as
a survival factor in cancer cells, especially KRAS-dependent lung cancer cell
lines45,60,62,66. TBK1 knockdown by RNA interference in these human cancer cell
lines promotes their apoptosis and suppresses their growth as xenograft tumors in
immunocompromised mice45,60,66. The TBK1 knockdown has also been shown to
sensitize tamoxifen-resistant breast cancer cells to tamoxifen treatment72. Despite
these findings, the role of TBK1 in cancer regulation remained unclear and
controversial prior to the commencement of this dissertation project. A recent study
suggested that TBK1 knockdown by the majority of the TBK1 shRNAs has no
specific effect on the survival of either KRAS-dependent or KRAS-independent
human cancer cells, suggesting a potential off-target effect of the shRNAs used in
previous studies73. Furthermore, pharmacological inhibition of TBK1 fails to
significantly reduce the rate of cancer cell growth, despite the efficient blockade of
the canonical TBK1 function in IRF3 phosphorylation73. These findings cause some
confusion in the field that obviously warrants additional studies.
As described in Chapter 3 of this dissertation, our study using Tbk1IEC-KO mice
in conjunction with the Apcmin/+ animal model of colon cancer has revealed an
inhibitory role for TBK1 in regulating adenoma development. However, the role of
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TBK1 in regulating the late-stages of CRC remains to be examined. We addressed
this question by knocking down TBK1 in CRC cells and performing tumor formation
studies using a xenograft model. In addition, we also employed a small molecule
inhibitor of TBK1, MRT67307. While we have presented in this dissertation the
limitations of these models, we found that TBK1 is dispensable for the survival of
KRAS-competent human colon cancer xenograph tumors. We speculate that this
may be attributable to the absence of T lymphocytes in this model.
Results
To knock down TBK1 in human CRC cells, we transduced human CRC HT-29
cells with either a control shRNA targeting luciferase or two different TBK1 shRNAs,
TBK1 shRNA D5 and D9. The HT-29 cell line is a frequently used CRC cell line that
carries APC mutations104,105 but is KRAS wildtype. These cells resemble our animal
studies using the Apcmin/+ mice in Chapter 3 in that they have deregulated Wnt
signaling due to impaired APC function. Since TBK1 shRNA D5 had a much higher
knockdown efficiency than TBK1 shRNA D9 (Figure 22A), we used the D5transduced HT-29 cells for the xenograft model of studies. To avoid rejection of the
human cells by mouse immune system, we used the lymphocyte-deficient nude
(nu/nu) mice as recipients for human colon cancer cell xenograft transplantation106.
We injected the control or TBK1 shRNA D5 knockdown HT-29 cells into nu/nu mice
subcutaneously at two sites per mouse, measured the tumor size twice each week,
2

and calculated tumor volume based on the formula volume = (length x width ) x 0.52.
We observed that TBK1 knockdown in HT-29 cells had no effect on size of tumors
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developing in the immunodeficient xenograft mouse model (Figure 22B, C and D).
Thus, TBK1 is dispensable for the growth and survival of CRC HT-29 cells under
xenograft conditions.
Since TBK1 has been implicated in the survival regulation of KRASdependent cancer cells60,62,66,73, we next performed TBK1 knockdown in a CRC cell
line, LoVo, a known to carrier of KRAS mutations. We used the more efficient TBK1
shRNA D5 to knockdown TBK1 in LoVo cells and analyzed cell growth and cell
death in culture.

After TBK1 knockdown in vitro (Figure 23A), LoVo cells had

decreased cell numbers and cell viability over time compared to control cells
transduced with the luciferase shRNA-encoding vector (Figure 23B, C and D). This
result is consistent with the claim in the literature that TBK1 mediates the survival of
KRAS-dependent cancer cells60,62,66,73.
To elucidate the molecular mechanism by which TBK1 mediates LoVo cell
growth and survival, we examined the effect of TBK1 knockdown on the activation of
two major kinases, AKT and mTORC1, associated with cell growth and survival. We
measured the activation of AKT based on its phosphorylation at serine-473 and the
activation of mTORC1 based on phosphorylation of a downstream protein, S6. We
used the HT-29 cell line as a control, since the growth and survival of these cells are
insensitive to TBK1 knockdown. Interestingly, the TBK1 knockdown by shRNA D5
resulted in inhibition of AKT activation in both the HT-29 and LoVo cells, although
the effect on S6 phosphorylation was somewhat variable (Figure 24). This finding
was intriguing, since TBK1 knockdown had no obvious effect on the growth of HT-29
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in the xenograft model. It is possible that the reduction in AKT phosphorylation may
be compensated by some other signaling pathways, particularly those downstream
of the KRAS. It is also important to note that this result is based on only one TBK1
shRNA, since the shRNA D9 was inefficient in TBK1 knockdown.
The pharmacological compound MRT67307 is a TBK1 inhibitor that has been
shown to inhibit the induction of IRF3 phosphorylation and IFN-β production in
macrophages107. Since the process of shRNA knockdown is long, the system may
have the potential problem of selecting abnormal cell populations with a growth
advantage. So, we performed independent studies by employing the TBK1 inhibitor
MRT67307. Surprisingly, MRT67307 treatment did not appreciably affect the
phosphorylation of AKT as revealed using the TBK1 knockdown system with HT-29
and LoVo cells (Figure 25). Moreover, this treatment led to the drastic induction of
S6 phosphorylation, indicative of mTORC1 activation. The reasons for these
contradictory results are unclear, but may be due to transient nature of
pharmacological inhibition as compared to the stability of the knockdown system.
Discussion
The results of this study suggest that TBK1 is dispensable for the growth and
survival of CRC HT-29 cells under xenograft conditions. Taken together with our
animal studies using Apcmin/+ mice described in Chapter 3, these findings suggest
that TBK1 may not be involved in the intestinal tumor growth and/or survival of the
CRC cells under KRAS-competent conditions.

Furthermore, our animal studies

under lymphocyte-free conditions in Chapter 3 revealed that the tumor-regulating
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function of TBK1 is dependent upon the presence of functional lymphocytes.
Therefore, it is possible that the function of TBK1 in CRC cell xenograph tumor
growth may be masked by the absence of functional T lymphocytes.
The results of this study suggest a role for TBK1 in regulating the survival of a
KRAS-dependent CRC cell line, LoVo, although not a KRAS-independent cell line,
HT-29. This finding KRAS-dependent function of TBK1 is consistent with the
previous work performed using lung cancer cell lines though the underlying signaling
mechanism of this function is still unclear. Our attempt to elucidate this molecular
mechanism revealed some inconsistent results. While TBK1 knockdown using
shRNA suggests a role for TBK1 in mediating activation of AKT, inhibition of TBK1
with a pharmacologic inhibitor surprisingly did not lead to AKT inhibition. Instead, the
TBK1 inhibitor strongly promoted the phosphorylation of S6, a downstream target of
the metabolic kinase mTORC1. The reasons for conflicting results are unclear. As
discussed above, one difference between the pharmacological inhibition and the
shRNA knockdown strategies is that the former is a more transient event, whereas
the latter represents a more steady state following a long period of cell selections.
Another possibility is that MRT67307 may non-specifically inhibit additional kinases,
thus causing the activation of the mTORC1 pathway. Alternatively, these results
may reflect the loss of the adaptor function of TBK1 in knockdown systems
compared to the blockade of the kinase function of TBK1 using TBK1
pharmacological inhibitor. This is possible given that other domains such as the
ULD, SDD, and CTD of TBK1 mediate the recruitment of TBK1 to specific binding
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partners and the substrate specificity and phosphorylation by TBK141-43,45,84. Clearly,
these studies further highlight the high levels of variations in in vitro studies using
cancer cell lines, emphasizing the necessity of additional studies using different
approaches including genetic animal models as presented in Chapter 3 and the
recently developed CRISPR-knockout system.

.
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Figure 31. TBK1 knock-down in human colon cancer cell line HT-29 has no
effect on tumor size in a mouse xenograft model.

A

B!
HT-29 human colon cancer cell line!
Control

D5

D9!

TBK1!
HSP60!

Tumor Size (mm3)!

shRNA:!

1600"
1400"
1200"
1000"

HT-29Control
Control!
HT-29
!
shRNA!

800"
600"
400"

HT-29
HT-29TBK1
TBK1d5D5!
shRNA!
!

200"
0"
3"

7"

13"

17"

21"

Days!

C!

D!
Weight (g)!

28!
27!
26!
25!

HT-29control!
Control!
HT-29

24!

HT-29TBK1
TBK1D5!
D5!
HT-29

23!
22!
7!

HT-29 Control!

13!

17!

Days!

HT-29 TBK1 D5!

131

21!

Figure 31. TBK1 is dispensable for xenograph tumor growth using KRAScompetent human HT-29. A) Western blot analysis of TBK1 in HT-29 cells
transduced with a vector encoding a TBK1 shRNA (D5 or D9) or a control luciferase
shRNA (control shRNA). B) Growth curve of xenograph tumors grown in nu/nu mice
(n=5 each group; two tumors per mouse) injected subcutaneously with HT-29 cells
transduced with control luciferase shRNA- or TBK1 D5 shRNA-encoding vectors.
Data are presented as mean ± SD and are a representative of two independent
experiments. C) Representative image of tumor sizes at day 21 post-injection of
nu/nu mice with HT-29 cells transduced with control shRNA- or TBK1 D5 shRNAencoding vectors. D) Change in weight (g) of the nu/nu mice post-injection with HT29 cells transduced with control shRNA- or TBK1 D5 shRNA-encoding vectors. Data
are presented as mean ± SD.
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Figure 32. TBK1 knockdown in LoVo cells reduces cell viability in vitro.
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Figure 32. TBK1 knockdown in LoVo cells reduces cell viability in vitro. A)
Western blot analysis of TBK1 in LoVo cells transduced with a vector encoding a
TBK1 shRNA (D5) or a control luciferase shRNA (control shRNA). LoVo cells
transduced with control luciferase shRNA- or TBK1 D5 shRNA-encoding vectors
were seeded at B) 50 × 103 cells/well or C) 500 × 103 cells/well. Live (top B and C)
and dead (middle B and C) cells were counted at indicated days post-seeding using
trypan blue exclusion. Cell survival was determined as the percentage of dead cells
(bottom B and C) in total cells counted. D) Representative images of LoVo cells
transduced with a vector encoding a TBK1 shRNA (D5) or a control luciferase
shRNA (control shRNA) in culture at days 1 and 4 post-seeding. Data represents
one experiment.

134

Figure 33. TBK1 knockdown in CRC cells inhibits AKT and mTORC1
activation.
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Figure 33. TBK1 knockdown in CRC cells inhibits AKT and mTORC1
activation. Western blot analysis of the indicated proteins in whole-cell lysates from
HT-29 and LoVo cells stably transduced with control luciferase shRNA- or TBK1
shRNA-encoding vectors as indicated.
experiments.
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Data represents three independent

Figure 34. Pharmacological inhibition of TBK1 activates AKT and mTOR
pathways in CRC cells.
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Figure 34. Figure 25. Pharmacological inhibition of TBK1 activates AKT and
mTOR pathways in CRC cells. Western blot analysis of the indicated proteins in
whole-cell lysates from HT-29 and LoVo cells with MRT67307 (TBK1 inh) or dimethyl
sulfoxide (DMSO) at indicated times (hours).
experiments.
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Data represents two independent
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Chapter 5: Overview, Discussion and Future Directions
The primary objective of this work was to determine the role of TBK1 in the
tumorigenic process in vivo. We present the first in vivo model to demonstrate
TBK1’s function during intestinal adenoma development and suggest a mechanism
of TBK1 action. Moreover, this project presents the use of a novel approach in
determining TBK1’s role in early cancer development in vivo in addition to the
xenograft model currently described in the literature for other cancer types. The
following sections will summarize and discuss the major findings of this dissertation.
1. TBK1 is a novel inhibitor of intestinal adenoma growth
In Chapter 3, we generated and characterized an innovative mouse model in
which TBK1 is conditionally deleted in IECs, leading to the discovery that TBK1 has
a tumor-suppressive function in the intestine. In particular, IEC-specific Tbk1 ablation
promotes adenoma development in mice carrying a heterozygous mutation in the
tumor suppressor Apc gene, an alteration commonly found in the earlier stages of
CRC development16.18

The effect of TBK1 deficiency on adenoma formation is

diminished in the absence of lymphocytes demonstrated herein by IEC-specific Tbk1
deletion in Apcmin/+ mice having no effect on the formation of intestinal polyps under
lymphocyte-free conditions. Those results suggest that IEC-specific TBK1 regulates
an aspect of adaptive immune homeostasis.
Moreover, intestinal T lymphocytes, specifically Tregs, are required for
immune homeostatic maintenance of the gut, suppressing inflammatory responses
to commensal organisms in an IL-10-dependent manner.
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33, 32

While IEC-specific

TBK1 does not seem to regulate IL-10 expression in intestinal Tregs in Apcmin/+ mice,
it is required for IL-10 expression by IELs, another major producer of intestinal IL1033, 32, during the early stages of the tumorigenic process. Indeed, intestinal IELs
suppression of intestinal inflammation is IL-10-mediated.39 Thus, we identified a new
role for TBK1 as an important facilitator of crosstalk between IECs and intestinal
IELs that controls the expression of Il10 under an Apcmin/+ background. It is important
to confirm impaired IL-10 protein levels in intestinal IELs upon IEC-specific Tbk1
deletion in Apcmin/+ mice to corroborate our findings. In later experiments, we will
perform IL-10-specific intracellular staining and use flow cytometry to determine IL10 protein expression in IELs at the single-cell level and we expect impaired IL-10
production by IELs after IEC-specific Tbk1 ablation.
Given that impaired IL-10 production in the intestine is linked to enhanced
inflammatory disease and intestinal tumorigenesis37,108-111, it is likely that the
diminished Il10 expression by the IELs contributes to the elevated adenoma
formation in the Apcmin/+Tbk1IEC-KO mice.

To confirm this, we are generating

Apcmin/+Tbk1IEC-KO mice on an IL-10-deficient background. We expect the difference
between Apcmin/+ and Apcmin/+Tbk1IEC-KO mice to be abolished after Il10 deletion.
The next question to be addressed is how TBK1 functions within IECs to
affect Il10 expression by IELs.

We hypothesize that TBK1 may regulate the

expression of either surface protein(s) or secretory factor(s) by IECs that in turn
induces IL-10 production by IELs.

Considering that the role of TBK1 is well

established in regulating type I interferon induction and that IL-10 is an interferon-
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responsive gene95,112-116, it is possible that TBK1 regulates the expression of type I
interferons by IECs thereby regulating IL-10 expression by IELs.

While the

expression levels of IFN-α and -β were comparable in the intestines of Apcmin/+ and
Apcmin/+ Tbk1IEC-KO mice, it is possible that potential differences in their expression
could be masked by lack of commensal stimulation of IECs during intestinal
preparation prior to analysis. To overcome this technical obstacle, we will stimulate
IECs with PRR agonists after intestinal preparation prior to analysis of type I
interferon expression. We expect defective type I interferon expression upon PRR
stimulation in IECs deficient in TBK1.
If TBK1 is dispensable for IFN expression by IECs, an alternative hypothesis
may be that TBK1 regulates the expression of transmembrane protein semaphorin
(Sema) 7A, thus regulating IL-10 expression by IELs. Semaphorins are classically
described as regulators of neuronal cell signaling but have recently been found to
function in various organs and cell types, including immune cells114. Specifically,
Sema7A is expressed in brain, lung, intestines, thymus, lymphocytes, and
macrophages117 to name a few. It is also expressed on thymocytes preferentially
during selection and during activation in the periphery46,57,116. Sema7a deficiency in
T cells leads to a reduction in inflammatory responses, whereas its overexpression
can stimulate macrophages and monocytes via interaction with α1β1 integrin to
secrete proinflammatory cytokines

118,119

. A recent study examined Sema7a in the

intestine and found that its expression on IECs induces IL-10 production by intestinal
macrophages to negatively regulate chemically-induced colitis120. We will examine
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the expression level of Sema7a in IECs of Apcmin/+ and Apcmin/+Tbk1IEC-KO mice. In
addition, we will employ a more systematic approach to compare gene expression
profiles between the IECs of Apcmin/+ and Apcmin/+Tbk1IEC-KO mice by RNA
sequencing. Together, these future studies will likely provide more insight into the
mechanism underlying the IEC-specific function of TBK1 in regulating adenoma
formation.
2. TBK1 is dispensable for growth and survival of KRAS-independent human CRC
cells
In Chapter 4, we employed a TBK1 knockdown system using KRASdependent and KRAS-independent human CRC cell lines, leading to the conclusion
that, under T lymphocyte-free conditions, TBK1 is dispensable for the growth and
survival of xenograph tumors derived from KRAS-independent human CRC cell
lines. However, consistent with earlier findings, TBK1 regulates the survival of a
KRAS-dependent CRC cell lines in vitro. Given the immunocompromised status of
the CRC cell recipient mice, it would be interesting to determine whether the tumorregulating function of TBK1 in KRAS-independent human CRC cells is masked by
the absence of T lymphocytes similar to what we observed in our study using
Tbk1IEC-KO mice in Apcmin/+ background. Furthermore, our attempt to elucidate the
molecular mechanism underlying this function of TBK1 was met with inconsistent
results further highlighting the need for multiple approaches to gain more insight.
As mentioned in Chapter 2, the use of animal models has revealed important
cellular and molecular players involved in CRC development and progression. One
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challenge in determining the in vivo function of TBK1 has been the embryonic
lethality of conventional Tbk1 KO mice56. In this project, we overcame this obstacle
by generating Tbk1 IEC-conditional KO mice, which provided genetic evidence that
TBK1 suppresses intestinal adenoma development by regulating the intestinal
adaptive immune system. It would be interesting to determine if the cell survival
function of TBK1 would persist in the presence of T lymphocytes since these studies
used immunocompromised hosts lacking T lymphocytes. Ironically, we show in
Chapter 4 that TBK1 deficiency in KRAS-independent human CRC cells had no
effect on xenograph tumor growth in immunocompromised hosts, a finding that
parallels our results in Chapter 3 where the IEC specific-TBK1 deficiency has little
effect on intestinal polyp formation in Apcmin/+ mice lacking lymphocytes. Further
studies are needed to determine if TBK1 regulates a part of the adaptive immune
homeostasis that is masked by the absence of T cells in xenograph tumor models.
Furthermore, we have shown here that TBK1 inhibits intestinal adenoma
development at early stages under an Apcmin/+ background. Because the survival
function of TBK1 has been mainly attributed to the human cancer cells dependent
upon KRAS, the question remains if TBK1 exerts similar or distinct functions in
different oncogenic pathways under lymphocyte-competent conditions. The findings
of this project begin to address this question, which could have significant clinical
implications and impact the direction of the field.

There is a strong and very

significant positive correlation between TBK1 expression and the expression of APC
in the patient samples of colorectal adenocarcinomas, a finding that is consistent
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with the results using our Apcmin/+ mice with IEC-specific Tbk1 ablation presented
herein. A similar trend – a strong and very significant positive correlation – was also
observed between expression of TBK1 and KRAS in patient samples. One could
hypothesize that TBK1 negatively regulates tumor progression in KRAS mutant
colon cancer given the strong relationship between expression of the two genes. In
support of this hypothesis, levels of TBK1 expression correlate positively between
early and late stages of disease. Thus one could speculate that TBK1 functions
similar in the late stages of colorectal cancer which have acquired KRAS and
PIK3CA genetic mutations as it does during early stages of disease where LOH of
APC commonly occurs.

Additional analyses testing this idea using KRAS and

PIK3CA in vivo models as presented in this dissertation using Apcmin/+ mice would
provide

a

better

understanding

of

the

advancement of the disease.
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molecular

mechanisms

mediating

Chapter 6 Materials and Methods
Mice. Age-matched Tbk1 intestinal epithelial cell-conditional KO (Tbk1IEC-KO) and
wildtype mice were generated by crossing Tbk1 floxed mice
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(Taconic) with villin-

Cre mice (Jackson Laboratory). IEC-conditional Tbk1 mice were further crossed with
Apcmin/+ mice (Jackson Laboratory) to generate Apcmin/+ or Apcmin/+Tbk1IEC-KO mice. In
some experiments, the Apcmin/+Tbk1IEC-KO mice were further crossed with Rag1-/(Rag1 KO) (Jackson Laboratory) mice to generate Apcmin/+ Rag1 KO or
Apcmin/+Tbk1IEC-KO Rag1 KO mice. The Tbk1 floxed mice had a 129Sv/Ev
background, villlin Cre transgenic mice had a mixed background, the Apcmin/+ and
Rag1 KO mice were of C57BL/6 background. The mice were maintained at The
University of Texas M.D. Anderson Cancer Center facility under specific pathogenfree conditions. Animal experiments were performed in accordance with protocols
approved by the Institutional Animal Care and Use Committee.

Antibodies and reagents. Antibodies for recognizing TBK1, phospho-AKT ser473
(D9E), AKT1 (B-1), phospho-S6 Ser235/236 (D57.2.2E), and S6 (54D2) were from
Cell Signaling. β actin (C-4), HSP 60 and HSP 70 were from Sigma Aldrich. The
MRT673037 TBK1 inhibitor was from Chemexpress.

Cell lines. The human colon cancer cell lines HT-29 and LoVo and the human
embryonic kidney (HEK) 293 cells were cultured in DMEM (Dulbecco’s modified
Eagle’s medium) supplemented with 10% FBS and 1% streptomycin/penicillin.
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Gene silencing. To produce the lentiviral particles, the pLKO.1 vectors encoding
control luciferase or encoding specific TBK1 shRNA (either TBK1 shRNA D5 or D9)
were transfected into HEK293 cells (using the calcium method) along with the
packaging vectors psPAX2 and pMD2 provided by X. Qin. Human colon cancer cell
lines were then infected with packaged viruses carrying either luciferase, TBK1
shRNA D5 or TBK1 shRNA D9. After 48 hours, infected cells were treated with
puromycin (1 ug/mL) for seven days to select for vector positive cells.

IEC isolation. Intestines were harvested, cut longitudinally and wash with PBS to
remove fecal contents. Intestines were incubated in HBSS (Hank's Buffered Salt
Solution) containing 10 mM EDTA at 37°C for five minutes in water bath.
Supernatants were discarded and intestines incubated with PBS containing 1 mM
EDTA and 1 mM DTT for 15 minutes in 37°C water bath. Suspension was shook
vigorously and supernatants were collected and washed twice with ice-cold PBS.

IEL and LP cell isolation. Mice were sacrificed and intestine resected. Feces were
removed by flushing with cold HBSS. The intestines were longitudinally opened, cut
into ~0.5cm pieces and incubated in Solution I (5% FBS, 2 mM EDTA, 1mM DTT, 10
mM HEPES in HBSS) at 37°C for twenty minutes. Pieces were vortexed briefly and
pass intestine through a (100 micron) filter. Supernatant were collected as IELs and
IECs. New Solution I was added to the intestinal pieces and subsequent steps
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repeated to collect more IELs. Intestinal pieces were then rinsed with HBSS with
10mM HEPES and supernatant combined with IEL and IEC collected.

Percoll

density gradient or CD45 bead separation was used to enrich for IELs. Intestinal
pieces were incubated in Solution II (5% FBS, 1 mg/mL Collagenase D, 0.1 mg/mL
Dnase I in RPMI 1640) at 37°C for 30 minutes. Suspension was vortexed briefly and
filtered to collect the lamina propria cells. New solution II was added to the intestinal
pieces and subsequent steps repeated.

Flow-through was combined and

suspension was centrifuged at 300g for ten minutes. Supernatant was discarded
and LP cells were stained with antibody or used in indicated experiments.

Bromodeoxyuridine (BrdU) assay.

BrdU incorporation assay was performed

according to manufacturer’s (Life Technologies) instructions. Six to eight week old
mice were injected with BrdU (Sigma-Aldrich) intraperitoneally at 50 ug per gram of
mouse body weight. Five hours after injection, mice were sacrificed and intestines
were resected and fixed in 10% Buffered Formalin Phosphate (Fisher Scientific)
overnight. Intestines were cleaned of feces, swiss-rolled, and paraffin-embedded.
Five micron BrdU-labeled tissue sections were deparafinized using xylene, hydrated
in series of graded ethanol as preparation for BrdU immunohistochemical staining.
Per the manufacturer’s kit, tissue sections were peroxidase quenched, trypsinized,
denatured, blocked and incubated with biotinylated anti-BrdU antibodies.

After

washing with PBS, tissue was incubated with streptavidin-peroxidase, rinsed,
developed, and counterstained. After tissue dehydration, tissue was mounted using
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Permount (Fisher Scientific).

Tissues were analyzed using brightfield filters of

Olympus BX41 microscope with Olympus DP70 camera. BrdU positive cells were
counted using count tool of Adobe Photoshop CS4 software and counting the
number of positively labeled cells and hematoxylin stained nuclei of either crypt,
villus, or microadenoma within the image from which percentage positive was
determined per crypt, per villus, or per microadenoma.

TUNEL assay. For TUNEL staining, the DeadEnd Fluorometric TUNEL System
(Promega) was employed. Per the manufacturer’s instructions, formalin fixed five
micron paraffin-embedded tissue sections were deparafinized and dehydrated using
xylene and graded ethanol washes.

Sections were immersed in 0.85% NaCl

followed by PBS washing and 10% buffered formalin fixation. After PBS washing,
sections were digested using Proteinase K solution at 20 ug/mL for 20 minutes at
room temperature. Sections were PBS washed and refixed in 10% buffered formalin
and rewashed in PBS. Sections were biotin blocked using Avidin/Biotin Blocking Kit
from Vector Laboratories, Inc. After washing in PBS, sections were equilibrated
using manufacturer-provided equilibration buffer in the TUNEL System kit.
Fragmented DNA within cells were fluorescein-labeled for one hour at 37°C by using
rTdT reaction mix provided by the TUNEL System kit. The reaction was terminated
and washed in PBS. Prolong gold anti-fade reagent plus DAPI (Life Technologies)
was used for tissue mount. Tissues were analyzed using fluorescent filters on
Olympus BX41 microscope with an Olympus DP70 camera. TUNEL positive cells
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were blindly counted using count tool of Adobe Photoshop CS4 software and
counting the number of positively labeled cells and DAPI stained nuclei of the villus
within the image from which percentage positive was determined per villus. For the
microadenomas, TUNEL positive cells were counted using count tool of Adobe
Photoshop CS4 software while DAPI stained nuclei were counted using Cell Profiler
version 3 cell image analysis software (http://www.cellprofiler.org).

The analysis

pipeline included identifying region of microadenoma and cropping within individual
image, saving cropped images for subsequent identification and automated
enumeration of DAPI stained nuclei as determined by automated image
thresholding.

Xenograft injection. Transduced HT29 cells with TBK1 shRNA (TBK1 KD) (2 × 106
cells) or control luciferase shRNA (2 × 106 cells) that were injected into
immunodeficient nu/nu mice (n=5 each group; two injected tumors per mouse)
subcutaneously. Tumor size was measured twice per week and tumor volume was
calculated using the defined formula (tumor volume = (length x width2) x 0.52).
Weight of the mice was measured twice per week post injection.

Ki67 immunohistochemical staining. Mice were sacrificed and intestines were
resected and fixed in 10% Buffered Formalin Phosphate (Fisher Scientific) overnight.
Intestines were cleaned of feces, swiss-rolled, and paraffin-embedded. Tissue
sections were deparafinized using xylene, hydrated in series of graded ethanol as
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preparation for immunohistochemical staining.

Antigen was retrieved by boiling

tissue section in Citrate Buffer pH 6 (Sigma-Aldrich) for 20 minutes. Tissue was
allowed to cool to room temperature, was blocked using 3% BSA in PBS, and
incubated overnight with Ki67 (D3B5) antibody (Cell Signaling).

After one hour

incubation with secondary antibody, tissue was developed using DAB substrate kit
(Abcam). Tissues were blindly using bright field filters of Olympus BX41 microscope
with Olympus DP70 camera and counted blindly using Adobe Photoshop CS6 count
tool.

Western blot. Whole-cell extracts of the cells were harvested using cell extraction
buffer containing 50 mM Tris, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.5%
deoxycholate, 1 mM phenylmethylsulfonyl fluoride, 50 mM p-nitrophenyl phosphate
and 0.3 μM Aprotinin. Samples were extracted for ten minutes on ice and
centrifuged at 13,000 RPM for one minute at 4°C. Lysates were analyzed for protein
quantity using Bradford assay. Proteins were separated using SDS-PAGE and
proteins were transferred to nitrocellulose membrane. Membranes were blocked
using 5% non-fat dry milk at room temperature for one hour. Membranes were
incubated with primary antibody indicated overnight at 4°C. Detection was performed
using enhanced chemiluminescence reagents and exposed to light film.

Flow cytometry. Single-cell suspensions of IELs and lamina propria immune cells
were subjected to flow cytometry using LSR II (BD Bioscience) flow cytometer.
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FlowJo software was used to analyze the data. The fluorescence-labeled antibodies
that were used included TCR γδ FITC-conjugated (BD bioscience), (eBioscience);
CD11c Pacific Blue-conjugated (BD Bioscience); CD45 PE-conjugated (BD
Bioscience); CD11b APC-Cy7-conjugated (BD Bioscience); and TCRβ APCconjugated (eBioscience).

Real-time quantitative RT-PCR (qPCR). For RNA extraction of tissues, intestines
were resected cleaned of feces using ice cold PBS. Tissues were flash frozen in
liquid nitrogen and ground using a pestle and mortar. Total RNA was isolated using
TRIzol reagent (Invitrogen) and subjected to cDNA synthesis using RNase H-reverse
transcriptase (Invitrogen) and oligo (dT) primers. For cells, TRIzol reagent was
added directly.

Real-time quantitative PCR was performed in triplicates, using

iCycler Sequence Detection System (Bio-Rad) and iQTM SYBR Green Supermix
(Bio-Rad). The expression of individual genes was calculated by a standard curve
method and normalized to the expression of beta-actin. The gene-specific primer
sets used (all for mouse genes) were as follows in the table below.
Gene

Primer

Primer sequence

mIl10

forward

CCAGAGCCACATGCTCCTAGA

reverse

GGTCCTTTGTTTGAAAGAAAGTCTTC

forward

CATCTTCTCAAAATTCGAGTGACAA

reverse

CCAGCTGCTCCTCCACTTG

forward

CACAGAGGATACCACTCCCAACA

mTnfα

mIl6
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mIl17a

mCxcl9

mCxcl10

mCxcl11

mCcl2

mIfnb

mIfna

mIfng

mIl17f

mLgr5

mAxin2

reverse

TCCACGATTTCCCAGAGAACA

forward

AGCGATGGTGGATGGCTCATGGTTAG

reverse

AGCTTTCCCTCCGCATTGACACAG

forward

TAGGCAGGTTTGATCTCCGT

reverse

CGATCCACTACAAATCCCTCA

forward

CCTATGGCCCTCATTCTCAC

reverse

CTCATCCTGCTGGGTCTGAG

forward

CGCCCCTGTTTGAACATAAG

reverse

CTGCTGAGATGAACAGGAAGG

forward

GGGATCATCTTGCTGGTGAA

reverse

AGGTCCCTGTCATGCTTCTG

forward

AGCTCCAAGAAAGGACGAACAT

reverse

GCCCTGTAGGTGAGGTTGATCT

forward

AGTCCATCAGCAGCTCAATGAC

reverse

AAGTATTTCCTCACAGCCAGCAG

forward

CAGCAACAGCAAGGCGAAA

reverse

CTGGACCTGTGGGTTGTTGAC

forward

CCCATGGGATTACAACATCACTC

reverse

CACTGGGCCTCAGCGATC

forward

TCCAACCTCAGCGTCTTC

reverse

TGGGAATGTGTGTCAAAG

forward

TCCATACAGGAGGATGCTGAAG
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mMuc2

mBclXL

mIl22

mIl1β

reverse

TTCGTCACTCGCCTTCTTGA

forward

ATGCCCACCTCCTCAAAGAC

reverse

GTAGTTTCCGTTGGAACAGTGAA

forward

TCTGAATGACCACCTAGAGC

reverse

GGTCAGTGTCTG GTCACTTC

forward

TCCGAGGAGTCAGTGCTAAA

reverse

AGAACGTCTTCCAGGGTGAA

forward

AAGCCTCGTGCTGTCGGACC

reverse

TGAGGCCCAAGGCCACAGGT

Mouse Reg3b qPCR primers set (Primer Pair ID M_Reg3b_1- gene ID 18489) was
purchased from Sigma-Aldrich.

AOM and DSS experiments. For the chemical-induced colitis model, mice were
treated with dextran sodium sulfate (DDS)121 (MP Biomedical LLC) as indicated for
either five or seven days with two-day water recovery period70. Mice were weighed
once per day during this treatment period and sacrificed at day two after water
recovery. The small intestine and colons were resected, formalin-fixed, sectioned, H
& E stained, and histologically scored based on the criteria in Table 1. For the
carcinogen-induced, chronic inflammation-induced colon cancer model, mice were
treated with a single dose of azoxymethane (AOM) (Sigma-Aldrich) and three cycles
of 2.5% DSS for five days and water for 14 days92. Mice were weighed once per
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week throughout treatment. After sacrificing the mice, the colons were resected,
measured in length, and formalin-fixed overnight. Intestines were cleaned of feces
and polyps were counted using Olympus SZX10 stereomicroscope.

Adenoma and microadenoma analysis. For intestinal adenoma analyses, mice
were sacrificed and intestines were resected and formalin-fixed overnight. Intestinal
feces were cleaned out and tissues were cut longitudinally. Using Olympus SZX10
stereomicroscope, Olympus DP70 camera, and Olympus CellSens Standard
software, adenomas were counted and measured for length after staining with 0.2 %
methylene blue and decolorizing with ethanol.

For microadenoma analyses, mice

were sacrificed and intestines were resected and formalin-fixed overnight. Intestinal
feces were cleaned out and tissues were cut longitudinally and swiss-rolled.
Intestines were cleaned of feces, cut longitudinally, swiss-rolled, and paraffinembedded. H&E stained section at 100 micron intervals through 500 microns of the
intestinal tissue was scored for microadenomas defined as histological dysplastic
lesions characterized by focal areas of abnormally large gland(s)17.

Statistical analysis. GraphPrism 6 (GraphPad, La Jolla, CA, USA) was used where
indicated for two-tailed unpaired t-tests. p-values <0.05 and <0.01 correspond with
(*) and (**) respectively.

For TCGA dataset analyses, RNA expression were

analyzed using the RNASeqV2 data from validated and/or provisional genomic and
transcriptomic profiles of colorectal adenocarcinoma tumor samples and were
accessed on December 12, 2015 at www.cbioportal.org74. Copy-number and overall
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survival data were accessed similarly. GraphPrism 6 was used for statistical
analyses and graphing. The Pearson correlation test was used to examine
correlation between mRNA expressions and log2 copy-number of a gene in the
TCGA datasets where correlations indicated. The survival data were visualized as
correlation between mRNA expression or log2 copy-number of a gene and overall
survival and analyzed using the Pearson correlation test. One-way ANOVA with
Tukey’s multiple comparisons test was used to analyze mean differences in mRNA
expression levels between groups of putative copy-number alternations with the
exception of the putative amplification group (n=1) and visualized as mean ± 95%
confidence intervals with alpha of 0.05. The threshold for statistical significance in all
test was p<0.05 with two-sided analysis. p-values of <0.05, <0.01, <0.001, <0.0001
correspond with (*), (**), (***), and (***) annotations respectively.
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